

A01. Bariatric Surgery and Iron Deficiency Anemia: A Retrospective Cohort

J. AL Shami¹, G. Hijazi², G. Gandour³, H. Mcheimeche⁴

¹Department of General Surgery, King's College Hospital, London, UK

²Department of Infectious Disease, Jabal Amel Hospital, Tyre, Lebano

³Department of General Surgery, University of Balamand, Beirut, Lebanon

⁴Professor of Surgery, Al-Zahraa University Hospital, Beirut, Lebanon

INTRODUCTION

Bariatric surgery has been for a long time one of the most successful interventions when it comes to tackling obesity and preventing its complications. However, weight loss procedures do not come without shifting the balance in metabolism, through new metabolic and nutritional challenges.

AIM

Our study focuses on analyzing the association of **Iron Deficiency Anemia (IDA)** and its prevalence **post-bariatric surgery** to further deepen our understanding of such new realities in bariatric patients.

METHOD

A retrospective cohort study, where **3000** patients who underwent bariatric surgery, were selected from a single center, Al Zahraa University Hospital, from the years **2008 till 2018**.

Medical records were carefully reviewed for **demographics**, **type of surgery**, and **postoperative complications**, including **IDA**. The SPSS system was employed for our statistical analysis, in which emphasis was put on IDA incidence after primary and revisional bariatric surgeries.

CONCLUSIONS

Iron deficiency anemia is a complication worth understanding its incidence and impact post bariatric surgery, especially after surgical procedures such as **RYGB** with malabsorptive components. Although a low prevalence was noted, there is still a requirement for screening alongside nutritional monitoring.


Iron supplementation as a prophylactic **should be** tailored according to the type of bariatric surgery opted for, and the overall strategy of weight loss to ensure the **best care** for our patients.

RESULTS

23 patients (0.76%) had iron deficiency anemia post-primary bariatric surgery and 1 patient (0.03%) post-secondary, which showed statistical significance as a complication post-operative with a p-value of 0.044.

Type of bariatric surgery	RYGB	SG	MGB	Total
Number of patients who underwent primary bariatric surgery	158	2829	13	3000
Number of patients who underwent revisional bariatric surgery	58	62	24	144
Total	216	2891	37	3144

Type of bariatric surgery	RYBG	SG	MGB	Total
Distribution of patients who had IDA post primary bariatric surgery (%)	7	16	0	23
	4.43%	0.57%	0	0.76%
Distribution of patients who had IDA post revisional bariatric surgery (%)	1	0	0	1
	1.72%	0%	0%	0.69%
p-value		0.1	0.415	
	0.044			



All of the 24 patients developing IDA were females

ACKNOWLEDGEMENTS

This work would have never been done without the support of our families who were always there for us and who always encouraged us. We are extremely grateful for everyone who aided us in some way in our research.

REFERENCES

Malinowski SS. Nutritional and metabolic complications of bariatric surgery. Am J Med Sci. 2006;331(4):219-25.

CONTACT INFORMATION

Email: dr.jaafaralshami@gmail.com

Contact Number: +447445677380

A04. Surgical Sequencing in Complex Obesity Patients: Outcomes of Sequential Bariatric Procedures and Gallbladder Interventions

J. AL Shami¹, G. Hijazi², G. Gandour³, H. Mcheimeche⁴

¹Department of General Surgery, King’s College Hospital, London, UK

²Department of Infectious Disease, Jabal Amel Hospital, Tyre, Lebanon

³Department of General Surgery, University of Balamand, Beirut, Lebanon

⁴Professor of Surgery, Al-Zahraa University Hospital, Beirut, Lebanon

INTRODUCTION

Bariatric surgeries have evolved drastically over the years, increasing in **complexity**, and **diversity**. At the same, the stories of **revisional procedures** have become part of the routines of bariatric surgeons, with **gallbladder diseases** presenting an important associated factor of repeated surgeries.

AIM

Our study focuses on the **outcomes** of sequential bariatric procedures and their **association** with **gallbladder pathologies**, hence cholecystectomy.

METHOD

Our study applied a retrospective cohort design, where **3000** patients who underwent bariatric surgery, were selected from a single center, at Al Zahraa University Hospital from the years **2008 till 2018**.

Our investigation was centered around **144** patients who had undergone **revisional surgery**.

Surgical combinations such as Sleeve Gastrectomy (**SG**) with Roux-en-Y Gastric Bypass (**RYGB**) or RYGB with Mini Gastric Bypass (**MGB**) were observed in **comparison** regarding rates of **post-operative cholecystectomy**.

RESULTS

41 patients underwent SG+RYGB from which 12 had a cholecystectomy done with a statistical significance p-value of 0.021.

6 patients underwent SG+MGB from which 2 had a cholecystectomy done.

9 patients underwent RYGB+RYGB surgeries from which 2 had a cholecystectomy done.

6 patients underwent RYGB+MGB from which 1 patient had a cholecystectomy done.

48 patients underwent RYGB+SG from which 3 patients had a cholecystectomy done

None of the combinations of surgeries showed any statistical significance (p-value>0.05) except for SG+RYGB surgeries as seen in the Table.

Patients underwent cholecystectomy post revisional bariatric surgery			
Type of surgery (primary + revisional)	Number of patients who performed the surgery (from the overall population)	Number of patients who performed the cholecystectomy (from the total number who performed this surgery)	p-value
SG + RYGB	41	12	0.021
SG + MGB	16	2	0.665
RYGB + RYGB	9	2	0.114
RYGB + MGB	6	1	0.453
RYGB + SG	48	3	0.167

CONCLUSIONS

Bariatric surgical sequencing may have different **influences** on the **risk** of incidence of **gallbladder** diseases.

SG+RYGB was shown to have a **greater** risk in our study and may raise **concern** about the requirements of **prophylactic strategies** such as Ursodeoxycholic acid (UDCA) or concomitant cholecystectomy during redo surgery, or improved monitoring.

Our findings are of **added value** in helping professionals personalize bariatric strategies toward **better outcomes and fewer complications**

REFERENCES

- Sneineh MA, Harel L, Elnasasra A, Razin H, Rotmensch A, Moscovici S, Kais H, Shirin H. Increased incidence of symptomatic cholelithiasis after bariatric roux-en-Y gastric bypass and previous bariatric surgery: A single center experience. Obesity Surg. 2020;1-5.
- Griffen WO,Jr, Young VL, Stevenson CC. A prospective comparison of gastric and jejunoileal bypass procedures for morbid obesity. Ann Surg. 1977 Oct;186(4):500-9.
- Bastouly M, Arasaki CH, Ferreira JB, Zanoto A, Borges FGH, Del Grande JC. Early changes in postprandial gallbladder emptying in morbidly obese patients undergoing roux-en-Y gastric bypass: Correlation with the occurrence of biliary sludge and gallstones. Obesity Surg. 2009;19(1):22-8.

ACKNOWLEDGEMENTS

This work would have never been done without the support of our families who were always there for us and who always encouraged us. We are extremely grateful for everyone who aided us in some way in our research.

CONTACT INFORMATION

Email: dr.jaafaralshami@gmail.com
Contact Number: +447445677380

A05.Concomitant Cholecystectomy with Revisional Bariatric Surgery: A Necessary Standard or Case-by-Case Decision?

J. AL Shami¹, G. Hijazi², G. Gandour³, H. Mcheimeche⁴

¹Department of General Surgery, King’s College Hospital, London, UK

²Department of Infectious Disease, Jabal Amel Hospital, Tyre, Lebanon

³Department of General Surgery, University of Balamand, Beirut, Lebanon

⁴Professor of Surgery, Al-Zahraa University Hospital, Beirut, Lebanon

INTRODUCTION

One of the most controversial discussions in bariatric surgery is centered around the management of gallbladder pathology during revisional bariatric surgery.

Alongside the high **incidence of gallbladder stones post bariatric surgery** as a result of rapid weight loss, some professionals may advocate for prophylactic cholecystectomy, while others may suggest more selective approaches

AIM

Our paper focuses on studying the necessity of concomitant cholecystectomy during revisional bariatric surgery.

METHOD

Our study applied a retrospective cohort design, where **3000 patients** who underwent bariatric surgery, were selected from a single center, at Al Zahraa University Hospital from the years **2008 till 2018**.

144 of those patients underwent revisional bariatric surgery.

Our study compared the outcomes between patients who had a concomitant cholecystectomy (n=6) against those who needed such a procedure later (n=20).

RESULTS

*Our findings concluded that **only 4.16%** of cases received a **concomitant cholecystectomy**, while **13.88%** required the **procedure postoperatively**. Those who had concomitant cholecystectomy had ultrasound proven gallstone with symptoms prior to the revisional bariatric surgery.*

*Our results add to the discussion that considering prophylactic cholecystectomy **is not always warranted** and that many risk factors come into play for such a surgical decision. There was **no clinical statistical significance** (p-value: 0.835) correlating the ultrasound results to the need of cholecystectomy. Ursodeoxycholic acid has been proposed to be used as a preventive measure for gallbladder stone formation.*

Number of patients who underwent revisional bariatric surgery	Number of cholecystectomies done after revisional bariatric surgery	Number of concomitant cholecystectomies done along revisional bariatric surgery	Ultrasound results of patients who underwent cholecystectomy after revisional bariatric surgery		p-value	Ultrasound results of patients who did not underwent cholecystectomy after revisional bariatric surgery		p-value
			Normal	Cholelithiasis		Normal	Cholelithiasis	
144	20	6	0	20	0.835	118	0	0.178

CONCLUSIONS

Prophylactic cholecystectomy during revisional bariatric surgery remains a controversial discussion, however, our study has denoted on many levels that concomitant prophylactic cholecystectomy **is not a must unless clinically indicated** for the patient’s case, proven he has symptomatic gallstones and needs to be operated on.

Justification of prophylactic cholecystectomy has not been formally established. **Physicians should diverge towards a more conservative approach in gallstone formation prophylaxis** to tackle the rise of biliary complications and to try to explain to the patients all the drawbacks of every procedure and if possible, to try alternative methods to prevent concomitant or future procedures as the usage of ursodeoxycholic acid.

REFERENCES

- Lopes TL, Baron TH. Endoscopic retrograde cholangiopancreatography in patients with roux-en-Y anatomy. Journal of hepato-biliary-pancreatic sciences. 2011;18(3):332-8.
- Villegas L, Schneider B, Provost D, Chang C, Scott D, Sims T, Hill L, Hynan L, Jones D. Is routine cholecystectomy required during laparoscopic gastric bypass? Obesity Surg. 2004;14(2):206-11.
- Fobi M, Lee H, Igwe D, Felahy B, James E, Stanczyk M, Fobi N. Prophylactic cholecystectomy with gastric bypass operation: Incidence of gallbladder disease. Obesity Surg. 2002;12(3):350-3.

ACKNOWLEDGEMENTS

This work would have never been done without the support of our families who were always there for us and who always encouraged us. We are extremely grateful for everyone who aided us in some way in our research.

CONTACT INFORMATION

Email: dr.jaafaralshami@gmail.com
Contact Number: +447445677380

INTRODUCTION

Obesity is a global health challenge with significant morbidity and mortality, including an increased risk of cardiovascular disease, diabetes, and cancer¹. For patients unable to achieve weight loss through traditional lifestyle modifications, bariatric surgery remains the most effective intervention². However, due to its invasive nature and associated risks, minimally invasive alternatives like intragastric balloon (IGB) therapy have gained popularity³. IGBs are temporary, designed to induce satiety and promote weight loss. Despite their safety profile, complications such as nausea, vomiting, and, rarely, gastric outlet obstruction (GOO) can occur⁴.

AIM




To present a rare complication of an intragastric balloon and its management

METHOD

We present a case of a 49-year-old overweight individual with a history of intragastric balloon implantation four weeks prior. The patient's weight prior to placement was 102 kg, with a BMI of 34.1. The patient has been experiencing nausea, vomiting, abdominal pain, and distention for the past week. The current weight at presentation is 84 kg, resulting in a BMI of 28.4. Upon examination, the patient seems dehydrated and has abdominal tenderness and distension in the mid-abdomen. Laboratory results indicate a white blood cell count of 6.5, a C-reactive protein level of 10, and potassium level of 3.4. Computed Tomography Scan The abdomen has significant distension with a trapped balloon located in the pyloric area. Patient admitted to the surgical department overnight; intravenous fluid replenishment initiated and nasogastric tube inserted. The patient exhibited vomiting of foul-smelling food contents. Gastric lavage was performed with warm fluids until the effluent was clear. The patient was transported to the operating theatre the day following admission, where, under general anaesthesia, a balloon was deflated and retrieved from the stomach by upper endoscopy.

RESULTS

The patient was successfully treated with endoscopic deflation and removal of the balloon. This case underscores the importance of recognizing GOO as a potential complication of IGB therapy, even in the early post-insertion period. The CT images confirm the presence of a well-defined round foreign object (the intragastric balloon) within the stomach. The stomach may appear distended, consistent with obstruction. No obvious perforation or free air is seen, but delayed gastric emptying is likely. Endoscopic Images (Images): Show mucosal changes such as erythema, edema, and possible ulceration, indicating irritation and injury to the gastric lining. This is likely due to pressure from the intragastric balloon. Displays congested and edematous gastric mucosa, consistent with ongoing inflammation, likely due to impaired gastric emptying. Clearly shows the intragastric balloon positioned near the gastric outlet (pylorus), causing a mechanical blockage of the gastric exit (gastric outlet obstruction).



CONCLUSIONS

The pictures confirm that the patient developed gastric outlet obstruction shortly after intragastric balloon placement, manifested by endoscopic and radiologic evidence of obstruction and mucosal injury. Early intervention is necessary to avoid severe complications. Clinicians should maintain a high index of suspicion for GOO in patients presenting with persistent gastrointestinal symptoms after IGB, especially after the first week of placement, to ensure timely diagnosis and management.

REFERENCES

1. The GBD 2015 Obesity Collaborators. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017 Jul 6;377(1):13-27.
2. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. N Engl J Med. 2017 Feb 16;376(7):641-651.
3. Kumar N. Intra-gastric Balloon for Obesity: A Review. Gastroenterol Hepatol (N Y). 2017 Nov;13(11):682-688.
4. Alqahtani AR, Al-Darwish A, Mahmoud AE, et al. Short-term outcomes of endoscopic sleeve gastropasty in 1000 consecutive patients. Gastrointest Endosc. 2019 Dec;90(6):1131-1138.e2.

ACKNOWLEDGEMENTS

The authors would like to extend their sincere appreciation to the supporting doctors and technical staff of the Department of General Surgery, Misurata Medical Centre, Misurata, Libya.

CONTACT INFORMATION

Email: Dr.elzowawi@gmail.com
Mobile: +218 91-3140623

A15. INTRA GASTRIC BALLOON AS A FIRST STAGE IN THE SUPER OBESE PATIENTS. IS IT WORTHWHILE?

S. Mridha¹, I. Oberoi¹, S. Balchandra², N. Samuel³, P. Vasas³, S. Yeluri¹

Doncaster & Bassetlaw Teaching Hospitals NHS Trust, Doncaster, United Kingdom

INTRODUCTION

Patients with super obesity require complex treatment and staged approach for weight loss. Intra-gastric balloon (IGB) is an accepted modality for treatment of obesity. However the efficacy of IGB in the super obese patients as a first stage has not been clearly established.

AIM



The study aims to evaluate the efficacy of IGB as first stage in selected patient population.

METHOD

Patients who received IGB as a first stage procedure as part of a staged approach, in our unit, from 2011 to 2021 were included in a prospective database. Demographic data, and weight loss results before and after 6 months of balloon insertion were analysed using Microsoft Excel.

RESULTS

14 patients were included in the study. All patients received routine IGB support, followed by planned endoscopic removal. Balloon was taken out early from one patient due to intolerance. Majority of the patients were male (64.2%). Median body mass index (BMI) prior to balloon insertion was 66.95 kg/m² (interquartile range {IQR}: 55.8-72.5 kg/m²) with a median weight of 197.2 kg (IQR: 166-237 Kg). Median total weight loss for all patients at 6 months was 10.5 Kg (range: -4.9-39.6). Two patients gained weight and a third patient did not lose any weight.



CONCLUSIONS

IGB as a first stage procedure in patients with super morbidly obesity achieved limited reduction in weight. It appears to have limited value in making the 2nd stage safe. Further data is required before IGB can be established as a first stage approach in this patient population.

REFERENCES

Wiggins T, Sharma O, Sarfaraz Y, Fry H, Baker J, Singhal R: Safety and efficacy of 12-month intra-gastric balloon—series of over 1100 patients. *Obes Surg.* 2024;34:176-182.
<https://doi.org/10.1007/s11695-023-06953-0>

ACKNOWLEDGEMENTS

Thanks to John Finney and Katie Kirk for helping with data collection

CONTACT INFORMATION

Dr. Shoieb Mridha, SHO, General Surgery,
Doncaster & Bassetlaw Teaching Hospital
shoieb.mridha@nhs.net

A17. Efficiency of Cruroplasty as a Treatment of Gastro-Esophageal Reflux Disease in Morbid Obese Patients with Hiatus Hernia during Sleeve-Gastrectomy

A. Aosmali¹, Osama Taha², M.Abdelglil³, Mahmoud Abdelaal²

¹University Hospital of Derby and burton, London, United Kingdom; ²Plastic and Obesity Surgery Department, Assiut University Hospital, Assiut, Egypt; ³Mansoura university children hospital, Egypt

Introduction


The effect of LSG on GERD is controversial. Although concomitant hiatal hernia repair at the time of LSG is common and advocated by many, there are few data on the outcomes of GERD symptoms in these patients.

Aim

To analyse the impact of hiatal hernia repair (HHR) on gastro-oesophageal reflux disease (GERD) in morbidly obese patients with hiatus hernia undergoing laparoscopic sleeve gastrectomy (LSG).




Method

This retrospective cohort study analyzed 20 patients (ages 18-60) undergoing LSG with cruroplasty at Ain Shams hospitals. Outcomes from July 2018 to July 2019 focused on GERD improvement, BMI changes, and crural repair efficacy. Preoperative heparin and antibiotics were given; no catheters, drains, or postoperative heparin were used. Patients ambulated early, began a liquid diet within six hours, and were discharged the next day if stable.



Result

The study included 20 participants aged 20–55 years (mean 37.55 ± 11.77), with 75% female and 25% male. Their mean weight was 110.38 ± 20.54 kg, height 158.10 ± 6.98 cm, and BMI 43.55 ± 1.98. The average operative time was 399.95 ± 30.89 minutes, and hospital stays lasted 1.95 ± 0.76 days. GERD was present in 70%, sleep apnea in 40%, hypertension in 45%, dyslipidemia in 85%, and asthma in 15%. Diabetes affected 40%, with treatments split between oral (20%), insulin (41.7%), and both (38.3%). Additionally, 15% consumed alcohol, and 35% were smokers.



Variable	Preoperative	3 Months Postoperative	Significance
Size of H. Hernia			HS
- 0	0 (0.0%)	18 (90.0%)	
- 1	11 (55.0%)	2 (10.0%)	
- 2	9 (45.0%)	0 (0.0%)	
Esophagitis			HS
- No	5 (25.0%)	15 (75.0%)	
- Yes	15 (75.0%)	5 (25.0%)	
Gastritis			S
- No	15 (75.0%)	20 (100.0%)	
- Yes	5 (25.0%)	0 (0.0%)	

Comparison between preoperative data and 3 months postoperative

Most participants (65%) were non-smokers, and 95% did not consume alcohol. Other conditions such as DM (40%), dyslipidemia (65%), hypertension (25%), and sleep apnea (40%) were reported, with asthma being the least common (10%). Baseline GERD was present in 70% of participants. Figure 2 shows postoperative GERD symptoms, with 90% of participants reporting no symptoms and 10% experiencing mild symptoms, suggesting that the intervention was effective in minimizing GERD-related symptoms.

Conclusion

SG with HHR is feasible and safe, providing good management of GERD in obese patients with reflux symptoms. Small hiatal defects could be underdiagnosed at preoperative endoscopy and/or upper gastrointestinal contrast study. Thus, a careful examination of the crura is always recommended intraoperatively.

Reference

- Samakar K, McKenzie TJ The effect of laparoscopic sleeve gastrectomy with concomitant hiatal hernia repair on gastroesophageal reflux disease in the morbidly obese.
- Soricelli E, Casella G, Rizzello M, Cali B, Alessandri G, Basso N. Initial experience with laparoscopic crural closure in the management of hiatal hernia in obese patients undergoing sleeve gastrectomy.
- Salvador-Sanchis JL, Martinez-Ramos D, Herfarth A, Rivadulla-Serrano I, Ibañez-Belenguer M, Hoashi JS. Treatment of morbid obesity and hiatal paraesophageal hernia by laparoscopic Roux-en-Y gastric bypass.

Acknowledgements

University Hospital of Derby and Burton

CONTACT INFORMATION

Ahmed Aosmali, MD,MRCS England, MSc.

Higher Speciality Surgical Trainee

University Hospital of Derby and Burton NHS Foundation Trust

Ahmedmoatsem850@gmail.com

A18. The Outcomes of Revisional One Anastomosis Gastric Bypass Versus Revisional Roux-en-Y Gastric Bypass After Primary Restrictive Procedures

A. Aosmali¹, Osama Taha², M.Abdelglil³, Mahmoud Abdelaal²,

¹University Hospital of Derby and burton, London, United Kingdom; ²Plastic and Obesity Surgery Department, Assiut University Hospital, Assiut, Egypt; ³ Mansoura university children hospital, Egypt

Introductio


primary restrictive bariatric procedures, such as laparoscopic gastric banding and VBG, were once popular but often resulted in complications like weight regain and poor quality of life. LVSG also gained popularity but has shown long-term weight regain.

AIM

to evaluate the effectiveness of one-anastomosis gastric bypass (OAGB) as a revisional procedure for failed restrictive bariatric surgeries and compare its outcomes with those of Roux-en-Y gastric bypass (RYGB) in terms of weight loss, reflux symptoms, and complications.


Metho

d between May 2009 and December 2016, involved 348 patients with failed restrictive bariatric procedures. Patients underwent laparoscopic revisional gastric bypass, with 243 receiving one-anastomosis gastric bypass (OAGB) and 105 undergoing Roux-en-Y gastric bypass (RYGB). The study excluded patients with certain conditions and aimed to compare outcomes, focusing on weight loss, complications, and reflux symptoms.



Result

S Between May 2009 and December 2016, 348 patients underwent laparoscopic revisional bypass surgery after failed restrictive bariatric procedures. The mean age was 39.3 years, with a preoperative BMI of 37.5 kg/m². All surgeries were completed laparoscopically, averaging 71.5 minutes, with a 2.1-day hospital stay. R-OAGB was performed on 243 patients and R-RYGB on 105. R-OAGB resulted in greater weight loss (71.8% vs. 58.3%, p=0.032). The overall mortality rate was 0.2%, with higher leakage in the R-RYGB group (2.8% vs. 0.9%).




Parameter	R-OAGB	R-RYGB	p-value
Operative time (min)	57.7 ± 55.8	85.3 ± 44.5	0.023*
Mean of EWL%	71.8 ± 5.9	58.3 ± 6.6	0.032*
Minor complications	15 (6.2%)	12 (11.4%)	0.279
Major complications	27 (11.1%)	9 (8.6%)	0.946
Leakage	1 (0.4%)	3 (2.8%)	0.033*
Bleeding	1 (0.4%)	0 (0%)	0.481
Intractable reflux	52 (21.4%)	3 (2.9%)	0.001*
Hb 1 year post-op (g/dL)	8.2 ± 0.5	12.8 ± 3.2	0.030*
Iron deficiency	33 (13.5%)	5 (4.7%)	0.048*
Mortality	1	0	0.481

Operative Parameters and Complications Between Revisional-One Anastomosis Gastric Bypass and Revisional-Roux-en Y Gastric Bypass

R-OAGB has shorter operative times, higher EWL%, and more iron deficiency but higher reflux rates. Significant differences appear in operative time, reflux, and Hb levels.

Intractable reflux occurred in 21.4% of R-OAGB patients versus 2.9% in R-RYGB (p < 0.001). While 78.6% of R-OAGB patients reported no reflux (SS score <4), 97.1% of R-RYGB patients did. Among 52 R-OAGB patients with severe reflux, 18 were treated with proton pump inhibitors, 4 underwent Braun anastomosis, and 30 were converted to RYGB, with 3 showing no improvement. Reflux rates were highest among R-OAGB patients with prior VBG (25.2%) compared to LAGB (16.9%) and LVSG (14.3%).



Conclusio

B The R-OAGB is simple, safe, effective, and easy to learn with a better weight loss than R-RYGB, but it has a higher chance of reflux and anemia in long-term follow-up. R-OAGB has acceptable reflux rates after LAGB and LVSG, but not recommended after LVBG

Reference

1. Mason EE, Tang S, Renquist KE, Barnes DT, Cullen JJ, Doherty C, et al. A decade of change in obesity surgery.
2. Nightengale ML, Sarr MG, Kelly KA, Jensen MD, Zinsmeister AR, Palumbo PJ. Prospective evaluation of vertical banded gastroplasty as the primary operation for morbid obesity.
3. van Gemert WG, van Wersch MM, Greve JW, Soeters PB. Revisional surgery after failed vertical banded gastroplasty.

Acknowledgements

University Hospital of Derby and Burton NHS Foundation Trust

CONTACT INFORMATION

Ahmed Aosmali, MD,MRCS England, MSc.
Higher Speciality Surgical Trainee
University Hospital of Derby and Burton NHS Foundation Trust
Ahmedmoatsem850@gmail.com

A19. Outcomes of One Anastomosis Gastric Bypass in 472 Diabetic Patients

A. Aosmali¹, Osama Taha², M.Abdelglil³, Mahmoud Abdelaal²

¹ University Hospital of Derby and Burton, London, United Kingdom; ² Plastic and Obesity Surgery Department, Assiut University Hospital, Assiut, Egypt; ³ Mansoura University Children's Hospital, Egypt

Introduction


Morbid obesity and type 2 diabetes are rising rapidly, with 80% of diagnosed cases being obese (1). Metabolic surgery, particularly OAGB, offers effective diabetes remission, even for lower BMI patients, with fewer complications than Roux-en-Y gastric bypass (RYGB) (2).

Aims

The aim of the study is to evaluate the outcomes of OAGB in diabetic obese patients treated at the bariatric center, Also to assess whether OAGB could serve as an alternative to Roux-en-Y Gastric Bypass (RYGB) for managing diabetes in obese individuals. Additionally, the study investigates whether preoperative factors, such as Body Mass Index (BMI) and the usage of antidiabetic medication, can predict postoperative diabetes remission outcomes



Method

Between 2009 and 2015, 472 diabetic patients (349 women) underwent OAGB surgery, with comprehensive preoperative evaluation and follow-up by a multidisciplinary team. Pre- and postsurgical management followed NIH guidelines, with Barrett's esophagus and severe GERD patients redirected to RYGB surgery. A five-port technique was used for the procedure, and postoperative care included clear fluids, gradual food introduction.



Result

The study evaluated the outcomes of One Anastomosis Gastric Bypass (OAGB) on 472 diabetic patients, focusing on weight loss, HbA1c improvement, and diabetes remission over three years. At one year post-operation, the mean BMI significantly dropped from $46.8 \pm 7.2 \text{ kg/m}^2$ to $29.5 \pm 2.8 \text{ kg/m}^2$, and HbA1c reduced from $9.6 \pm 1.3\%$ to $5.7 \pm 1.5\%$. By the three-year follow-up, the mean BMI stabilized at $32.1 \pm 3.3 \text{ kg/m}^2$ with HbA1c at $5.8 \pm 0.9\%$.




Complications were minimal, with an overall rate of 6.8%. The most common issue was iron deficiency anemia (3.8%). Weight loss patterns showed rapid reduction within the first year, followed by slight weight regain over the next two years.

Preoperative Treatment of DM	No. of DM Remission	Percentage of DM Remission
No drugs	43/43	100%
Single oral drug	142/154	92.2%
Two oral drugs	139/146	95.2%
Three oral drugs	21/29	72.4%
Injection	52/100	52%

Diabetes remission rates according to the preoperative management of DM

The study achieved complete diabetes remission in 84.1% of patients at one year, increasing to 90.9% by year three among those with continued follow-up. Partial remission was observed in 7.8% of patients, while 7% showed improved diabetes control, and 1.1% exhibited no improvement. The remission rates were higher in patients using oral hypoglycemic drugs before surgery, with 95.2% remission for those on two oral medications. In contrast, only 52% of patients on insulin achieved remission.



Conclusion

OAGB is a simple, safe, effective, easy to learn and easy to reverse procedure. It has acceptable complications and mortality rates. Therefore, OAGB has the ability to be an excellent alternative to RYGB in the treatment of diabetic obese patients. BMI could not be used for the prediction of postoperative diabetic remission, but preoperative medication is a good predictive factor. Longer follow-up for diabetic remission is needed. Future prospective and large subjective trials about the impact of bariatric surgery on type 1 DM should be performed

Result

1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes : systematic analysis
2. Lee WJ, Ser KH, Lee YC, et al. Laparoscopic Roux-en-Y vs. mini-gastric bypass for the treatment of morbid obesity: a 10-year experience. Obes Surg.
3. Dixon JB. Obesity and diabetes: the impact of bariatric surgery on type-2 diabetes. World J Surg.

2009;33(10):2014–21

Acknowledgements

University Hospital of Derby and Burton

CONTACT INFORMATION

Ahmed Aosmali, MD,MRCS England, MSc.
University Hospital of Derby and Burton
Higher Speciality Surgical Trainee
Ahmedmoatsem850@gmail.com

A21.Unlocking the Gut–Brain Connection: Microbiota and Neurohormonal Pathways in Obesity and Bariatric Surgery

Dimitra Peristeri¹, Hywel Room²

1. Department of Upper GI Surgery, Musgrove Park Hospital, Somerset NHS Foundation Trust, UK


2. Upper GI and Bariatric Unit, East Suffolk and North Essex NHS Foundation Trust, UK

INTRODUCTION

Obesity is way more than excess weight—it is a complex, systemic disorder driven by metabolic, inflammatory, and neurohormonal dysregulation. Central to this network is the gut microbiota (GM), which orchestrates energy balance, appetite, and metabolism. Bariatric surgery (BS) offers dramatic weight loss and metabolic improvement, not only by anatomical alteration but by reshaping the GM–gut–brain axis.

METHODS

We synthesised current evidence from human and experimental studies exploring GM composition in obesity and post-BS, with a focus on neurohormonal mediators, including GLP-1, PYY, and bile acids. Literature was identified via PubMed, Medline and Scopus, with inclusion of translational studies highlighting microbiota-driven metabolic pathways.



RESULTS

Obese individuals exhibit reduced microbial diversity, an increased Firmicutes/Bacteroidetes ratio, and depletion of beneficial taxa such as Christensenellaceae, Lactobacillus, Bifidobacteria, and Akkermansia. These changes promote chronic inflammation, insulin resistance, and energy dysregulation. BS induces rapid, profound shifts in GM, enhancing production of short-chain fatty acids, modulating bile acid signalling, and stimulating anorexigenic hormones. The resulting recalibration of the gut–brain axis drives sustained appetite suppression, improved glucose homeostasis, and durable weight loss. Novel microbiota-targeted strategies—including prebiotics, probiotics, and faecal transplantation—show promise as adjuncts to surgery, particularly in patients with incomplete metabolic response.

	Related GM Changes	
	Increased relative abundance	Decreased relative abundance
RYGB	Proteobacteria, Bacteroidetes, Verrucomicrobia, Bacteroidaceae, Genera Escherichia, Akkermansia, Veillonella, Bacteroides, Streptococcus and Slackia	Firmicutes, Blautia
SG	Actinobacteria, Bacteroidetes, Rikenellaceae, Christensenellaceae, Blautia, Akkermansia, Eubacterium, Lactobacillus, Cyanobacteria, and Haemophilus	Firmicutes, Blautia
GLP-1 analogues	Bacteroidetes, Proteobacteria, Bacilli, Collinsella, Akkermansia and Clostridium	Alistipes

GLP-1 analogues	Clostridium Collinsella, Akkermansia and Bacteroidetes, Proteobacteria, Bacilli	Alistipes
-----------------	---	-----------

	RYGB	SG	GLP-1 analogues
Leptin	↓	↓	↓
Ghrelin	↓	↓	↓
GLP-1	↑	↑	↑
PYY	↑	↑	↑
OXM	↑	↑	↑

CONCLUSION

The GM-neurohormonal interface is a master regulator of obesity and post-surgical metabolic recovery. By decoding this axis, we can move beyond one-size-fits-all interventions toward personalised, microbiota-informed strategies, blending surgery, nutrition, and pharmacology. Harnessing the gut–brain dialogue may redefine obesity treatment and open new horizons for precision metabolic medicine.

REFERENCES

- 1.Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest [Internet]. 2017 Jan 3 [cited 2024 Jul 2];127(1):1–4. Available from: <https://pubmed.ncbi.nlm.nih.gov/28045402/>
- 2.Bray GA, Kim KK, Wilding JPH. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev [Internet]. 2017 Jul 1 [cited 2024 Jun 29];18(7):715–23. Available from: <https://pubmed.ncbi.nlm.nih.gov/28489290/>
- 4.Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) [Internet]. 2008 Sep [cited 2024 Jun 29];32(9):1431–7. Available from: <https://pubmed.ncbi.nlm.nih.gov/18607383/>

AKNOWLEDGEMENTS

None

CONTACT INFORMATION

demieperisteri88@outlook.com

Dr. Osamah Alabid, Consultant Bariatric Surgeon,
Dr. Haider Sultan, Consultant Bariatric Surgeon,
Dowaly Private Hospital, Baghdad. Iraq

INTRODUCTION

Both LSG and LGCP are restrictive bariatric operations used to treat obesity; however, they may require revisional procedures due to weight regain, food intolerance, gastroesophageal reflux disease (GERD), or other reasons.¹ Roux-en-Y gastric bypass (RYGB) and one-anastomosis gastric bypass (OAGB) are the most common types of revisional surgery.^{2 3} This study aims to compare the technical difficulties encountered during revisional surgery after both LSG and LGCP.

AIM

To assess the technical difficulties encountered in revisional bariatric surgery when converting **LSG** or **LGCP** to **Roux-en-Y gastric bypass (RYGB)** or **one-anastomosis gastric bypass (OAGB)**.

METHOD

Between 2020 and 2025, 37 patients required revisional surgery (from LSG or LGCP converted to RYGB or OAGB). All operations were performed by the same surgeon. Patients were divided into two groups according to their primary procedure (LSG or LGCP).

Operative technical challenges were assessed based on:

- Total operative time
- Time required to prepare the gastric pouch
- Intraoperative adhesions
- Bleeding
- Partial resection of the remnant stomach
- Hospital stay duration

RESULTS

Of the 37 patients included:

- 24 had prior LSG (11 converted to RYGB and 13 to OAGB).
- 13 had prior LGCP (5 converted to RYGB and 8 to OAGB).


The average operative time for conversion of LGCP to RYGB was 190 minutes, compared with 110 minutes for the LSG group. Conversion of LGCP to OAGB required an average of 140 minutes, compared with 78 minutes in the LSG group.

Most of the operative time was spent on gastric pouch preparation — approximately 110 minutes in LGCP cases versus 50 minutes in LSG cases.


Adhesions around the stomach were more frequent and denser in LGCP cases than in LSG. The estimated blood loss averaged 170 ml in the LGCP group versus 45 ml in the LSG group; no case required blood transfusion. Partial resection of the remnant stomach was necessary in three LGCP cases but in none of the LSG cases. Prolonged hospital stay (more than one day) was required in two LGCP cases and one LSG case.

CONCLUSIONS

Both LSG and LGCP may necessitate revisional bariatric surgery; however, conversions following LGCP are technically more challenging and demand higher surgical expertise compared with LSG.



LGCP to RYGB



LSG to RYGB

REFERENCES

1. Felsenreich D, Lading L, Beckerhinn P, et al. Update: 10 years of sleeve gastrectomy — the first 103 patients. *Obes Surg.* 2018; 28: 3586–3594.
2. Homan J, Betzel B, Aarts E, et al. Secondary surgery after sleeve gastrectomy: Roux-en-Y gastric bypass or biliopancreatic diversion with duodenal switch. *Surg Obes Relat Dis.* 2015; 11: 771–777.
3. Moszkowicz D, Rau C, Guenzi M, et al. Laparoscopic omega-loop gastric bypass for the conversion of failed sleeve gastrectomy: early experience. *J Visc Surg.* 2013; 150: 373–378.

ACKNOWLEDGEMENTS

The author extends sincere thanks to Al-Dawli Private Hospital, its management, anesthetists, and surgical staff for providing the facilities and support necessary to perform safe, efficient, and advanced bariatric surgery.

CONTACT INFORMATION

Dr. Osama Alabid
Email: oalabid@yahoo.com
Phone no: +964 781 182 2978

A23. Evaluation of One Anastomosis Gastric Bypass with Modified Fundoplication Using the Excluded Stomach as a Novel Antireflux Technique

Authors, Mostafa Mahran^{1,2} Reem Salah² Haitham Elmaleh² Osama Fouad²

1- Homerton University Hospital, London, United Kingdom 2- Ain Shams University Hospital, Egypt

INTRODUCTION

Gastroesophageal reflux disease frequently persists despite weight reduction, thereby diminishing anticipated improvements in quality of life following bariatric surgery. While one-anastomosis gastric bypass is metabolically effective, it may not completely manage reflux symptoms. This study assessed whether the incorporation of a modified fundoplication could enhance symptom control and health-related quality of life compared with OAGB alone

AIM

To evaluate the feasibility, safety, and efficacy of combining One Anastomosis Gastric Bypass (OAGB) with a novel modified fundoplication using the excluded stomach in the management of obesity associated with gastroesophageal reflux disease (GERD) and/or hiatus hernia.

METHOD

- Prospective randomised comparative study was conducted on 60 patients with obesity and GERD and/or hiatus hernia.
- Participants were randomly assigned into two equal groups: Group A underwent standard OAGB, and Group B underwent OAGB combined with modified fundoplication.
- All patients were assessed preoperatively using upper gastrointestinal endoscopy and esophageal manometry.
- Postoperative outcomes included GERD symptoms assessed by the GERD-HRQL questionnaire, VISICK score, PPI dependency, weight loss, operative time, and complications. Follow-up was conducted over a 24-month period.

RESULTS

Both groups showed similar excess weight loss percentages at 6, 12, and 24 months, with no significant difference ($p > 0.05$). The OAGB + fundoplication group showed significantly lower postoperative VISICK scores (median 2 vs. 4, $p < 0.001$) and reduced PPI usage duration ($p = 0.00014$). Manometric findings at two years post-op showed increased LES high-pressure zones in the fundoplication group (56.6% vs. 0%) and improved LES relaxation (23.3% vs. 13.3%). There was a slight increase in dysphagia in the fundoplication group, requiring careful patient selection.








Figure (17): Box plot between groups and VISICK score.



CONCLUSIONS

Overall, OAGB with modified fundoplication appears to be a feasible, safe, and effective alternative to conventional OAGB for patients with obesity, GERD, and/or hiatus hernia, reducing the need for long-term GERD management and potentially avoiding more invasive procedures like Roux-en-Y conversion.

REFERENCES

Petruciani et al. (2023) – A 10-year retrospective study analyzing factors contributing to **gastroesophageal reflux after gastric bypass**, highlighting long-term reflux risk despite bypass benefits.

Carbajo & Caballero (2002) – Introduced the **one-anastomosis gastric bypass (OAGB)** as a new technique aimed at reducing postoperative gastroesophageal reflux.

Al-Khyatt et al. (2023) – A systematic review and meta-analysis comparing **sleeve gastrectomy with hiatal hernia repair versus sleeve-fundoplication**, finding differences in efficacy for **GERD resolution**

ACKNOWLEDGEMENTS

Highlight this text and replace with your own text.

CONTACT INFORMATION

m.mahran1@nhs.net
dr.mahran@med.asu.med.eg

J. WAGNER¹, M. ROLL¹, A. LAUTENBACH¹, S. NOTZ¹, G. PLITZKO¹, J. IZBICKI¹, O. MANN¹, T. HACKERT¹, A. DUPRÉE¹, F. BRODERSEN¹, A. WEIGEL¹

¹ University Medical Center Hamburg-Eppendorf, Hamburg, Germany

INTRODUCTION

Currently, bariatric surgery is the most effective treatment for patients with obesity. While lifelong follow-up care is recommended to support long-term outcomes, follow-up attendance remains suboptimal [1]. The reasons for this are not yet fully understood.

AIM

To identifying patients’ needs to improve engagement in long-term follow-up care, this study aimed to assess unmet supportive care needs in patients following bariatric surgery using the SCNS-SF34.

METHOD

Patients who had undergone bariatric surgery at a university medical center and attended at least one follow-up appointment were invited to complete an adjusted SCNS-SF34 questionnaire online. The SCNS-SF34 is a validated instrument originally developed to assess supportive care needs in patients with cancer [2]. For this study, the questionnaire was adapted to the context of bariatric surgery and obesity care. To compare levels of unmet needs across SCNS-SF34 subscales within individuals, a fixed-effects linear regression model was applied. The model included subscales as categorical predictors and controlled for individual-level heterogeneity by using patient ID as the panel variable. To explore differences between patients with and without unmet supportive care needs, participants were categorized based on the presence of at least one response rated ≥4 ("some need" or "high need") in any SCNS-SF34 domain. This threshold was used to indicate an unmet need in line with established scoring procedures. Comparisons between groups were conducted using chi-square tests for categorical variables and two-sample t-tests for continuous variables. Differences in mean SCNS-SF34 domain scores between postoperative year groups were analyzed using one-way analysis of variance (ANOVA) with Bonferroni correction for multiple comparisons.

RESULTS

A total of 327 patients were contacted, of whom 260 participated in the study, yielding a participation rate of 79.5%. The mean age was 44 ± 11.1 years, and the majority were female (68%). The average preoperative weight was 151 ± 27.1 kg, with a mean BMI of 50.5 ± 7.9 kg/m². Surgical procedures included laparoscopic sleeve gastrectomy, Roux-en-Y gastric bypass (RYGB), and other techniques. At the time of data collection, patients had attended an average of 3.3 follow-up visits. The mean score for physical and daily living needs was 17.3 ± 21.8, the mean score for psychological needs was 21.3 ± 22.5, the mean score for sexuality needs was 17.5 ± 28.1, the mean score for patient care and support needs was 21.3 ± 22.5 and the mean score for health system and information needs was 26.1 ± 26. Next, we used a fixed-effects linear regression model to compare the needs levels within one patient. Health system and information needs score were significantly higher compared to each other category (Figure 1). A trend toward increasing need scores across all domains was observed during the first three postoperative years (Figure 2). Finally, we identified patients with high needs, defined by at least one response rated ≥4 ("some need" or "high need") in any SCNS-SF34 domain. Patients with high needs had a significantly lower weight (147kg ± 25.5 vs 156kg ± 27.7, p = 0.005) at the operation and were significantly smaller (172cm ± 8.7 vs 174cm ± 9.9, p = 0.018), albeit no difference in BMI was observed (p = 0.066). Additionally, patients with high needs were more often females (77.7% vs 59.2%, p < 0.001).

CONCLUSIONS

Needs assessment using a modified version of the SCNS-SF34 revealed generally low levels of unmet supportive care needs among patients after bariatric surgery. The highest scores were observed in the domain of health system and information needs. Improving patient education and communication regarding follow-up care may help enhance long-term adherence. Female patients more frequently reported high levels of need and may benefit from more individualized follow-up strategies.

REFERENCES

1. Puzifferri, Nancy et al. “Long-term follow-up after bariatric surgery: a systematic review.” JAMA vol. 312,9 (2014): 934-42. doi:10.1001/jama.2014.10706
2. Boyes, Allison et al. “Brief assessment of adult cancer patients' perceived needs: development and validation of the 34-item Supportive Care Needs Survey (SCNS-SF34).” Journal of evaluation in clinical practice vol. 15,4 (2009): 602-6. doi:10.1111/j.1365-2753.2008.01057.x

ACKNOWLEDGEMENTS

We thank all patients who participated in this study for their time and valuable contributions.

CONTACT INFORMATION

Jonas Wagner
www.uazh.de
jowagner@uke.de
adipositas@uke.de




Figure 1 Mean scores for each SCNS-SF34 domain. Data are presented as mean ± standard deviation. Statistical analysis was performed using a fixed-effects linear regression model to compare domain scores within individuals.

Figure 2 Mean SCNS-SF34 domain scores for physical and daily living needs (a), psychological needs (b), sexuality needs (c), patient care and support needs (d) and health system and information needs (e) by postoperative year. Data are presented as mean ± standard deviation. Statistical analysis was performed using one-way analysis of variance (ANOVA) with Bonferroni correction for multiple comparisons.



INTRODUCTION

History of Gastric Banding:

Non Adjustable bands:1970+
Adjustable bands: 1980+
The use of bands increased and got popularity since 2000+
> After 20210:-, Gastric bands started to decline gradually.

AIM


Why Gastric bandings became rare in Bariatric Practice:-.
-Poor weight loss compared to Laparoscopic Sleeve gastrectomy, Laparoscopic Gastric bypass, Laparoscopic Mini Gastric bypass, and Laparoscopic bipartition.
-Long Term complications (up to 52%). Long Term Reoperation (up to 66.1%). **Erosion (1.6%- 3%).**
-Other complications: Port and tube disconnection, Port infection\Abscess, Band slippage, Proximal Dilatation.

METHOD


From 2012- 2025, In 3 High volume Bariatric Centers in Kuwait (SRC Accredited).
1500+ Bariatric Cases.
Primary bands represented 1%.
Band Erosion:
Mostly due to Gastric wall Ischemia and Necrosis due to chronic over Inflammation.
Presentation: Variable
- Asymptomatic.
- Loss of Restrictive effect (weight regain)
- Epigastric Pain.
- Recurrent Port infection.
- Reflux\ Regurgitation.
- Fever\ Vomiting.
- Back Pain\ Splenic abscess.
Diagnosis:
- Clinical Suspicion.
- CT with oral contrast.
- Gastroscopy.
ONCE Diagnosed should be REMOVED
Removal Options:
- Endoscopy.
- Laparoscopy.
- Hybrid.

RESULTS


What is next:
- No revisional Surgery at time of removal of eroded gastric band (wait for 3-6 months)
Why revision is challenging:
- Depends on severity of erosion.
- Degree of fibrosis.
- Ischemic gastric pouch (Impaired vascularity)
MDT Assessment before deciding Revision:
- Full Labs, Barium, Esophageal Manometry, Gastroscopy, CT Volumetry, Dietary Assessment.
Surgical Options: LSG\GBPMGB\BPD\Bipartition/ in very selected cases ➡ Rebanding.
Recent Technologies:
Indocyanine injection& Robotic surgery:
- Improves visualization of tissue vascularity.
- Enhances intraoperative decision making.
- Reduces the risk of postoperative leaks and strictures.
- Assists in confirming adequate vascularization before completing an anastomosis or staple line.



Eroded gastric band laparoscopic removal



Endoscopic assessment after repair of erosion and removal



Repaired Stomach hole in layers



CONCLUSIONS

- Laparoscopic gastric banding is declining world wide.
- Gastric band erosion is a rare complication, management needs high level of suspicion for proper diagnosis and early removal.
- Post operative care needs MDT care.
- Revisional surgery is challenging, using recent technologies like ICD or Robotic assistance may help.

REFERENCES

1. Management of laparoscopic adjustable gastric band erosionPablo Quadri, Raquel Gonzalez-Heredia, Mario Masrur, Lisa Sanchez-Johnsen, Enrique F ElliSurgical endoscopy 31 (4), 1505-1512, 2017.
2. Endoscopic management of gastric band erosion: a systematic review and meta-analysis Ameya Deshmukh, Parth M Desai, Christine Ma, Vladimir Kushnir, Shaina Eckhouse, Francesca M Dimou, Thomas R McCarty, Ahmad Najdat Bazarbashi

ACKNOWLEDGEMENTS

DR.MOHAMMAD ALHAIFI-MY PERSONAL MENTOR IN BARIATRIC SURGERY

CONTACT INFORMATION

Dr. Ibrahim Abdelhamid Hassan
Hs_hanin2008@yahoo.com
+96597512146

DIMITRA V. PERISTERI¹, SAI SANDEEP SINGH ROWDHWAL²

¹ Bariatric and Upper GI Department, Somerset NHS Foundation Trust, United Kingdom

² General Surgery Department, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom

INTRODUCTION

Post-operative anastomotic leaks (AL) are one of the most challenging complications of bariatric surgery and can be detrimental. Indocyanine green (ICG) is a fluorescence dye that can provide a real-time intraoperative assessment of organ tissue perfusion. Its use in bariatric operations is still being debated.

AIM

The present review aims to evaluate the intraoperative utility of ICG during bariatric surgery to focus future research on a reliable tool to reduce the incidence of postoperative leaks.

METHOD

A systematic search of PubMed, EMBASE, MEDLINE, Scopus, and the Cochrane Library for published studies took place until December 2024, evaluating the use of ICG during bariatric surgical procedures. Studies were included if they assessed the ICG application in various bariatric operations to prevent and reduce AL rates.

RESULTS

Eleven studies were included, which involved a total of 887 patients. 643 patients underwent ICG-based intraoperative assessments, while 244 were in the control group. The mean age of participants was 43.8 years, and the mean BMI was 43.3 kg/m3. All included patients underwent various bariatric procedures. ICG was used alone in most studies, although it was mixed with methylene blue in one study. ICG administration protocols varied significantly. There were no reported complications from ICG administration. The utility of ICG has changed the intraoperative surgical decision-making of 4.2% of patients.

ICG is a safe and efficient tool to assist bariatric surgeons in early intraoperative detection of technical failures of the anastomosis /staple line and potentially prevent anastomotic leaks.

The findings support ICG’s role in improving intraoperative decision-making by providing real-time perfusion assessment and reducing the risk of anastomotic leaks without complications..



CONCLUSIONS

ICG is a promising technique for successfully preventing or timely managing AL in bariatric surgery. Large, randomized controlled studies are needed to confirm its utility for routine use in primary and revisional bariatric cases.

CONTACT INFORMATION

Dimitra V. Peristeri MD, MSc, PhD
Post-CCT Fellow in Bariatric and Upper GI Surgery.

Email:
demieperisteri88@outlook.com

A27. Ethical Considerations in Bariatric Tourism: A Qualitative Study of UK Patients with Postoperative Complications Abroad

Authors: G SHEWRING¹
University of Liverpool, United Kingdom

INTRODUCTION

Bariatric tourism = travelling abroad for privately funded weight-loss surgery.

Growing UK trend: ~10,000 people travel annually; Turkey is the leading destination.

Risks: High complication rates, inadequate aftercare

No prior UK-based qualitative study, exploring both clinician and patient perspectives

Aims	• Understand UK patients' motivations and expectations for bariatric surgery
	• Explore ethical issues in consent, information, and aftercare.
	• Capture NHS clinicians' experiences managing complications.
	• Identify policy and practice changes to improve safety.

METHOD

Design: Qualitative, interpretivist; semi-structured interviews

Sample: Patients n=5 (30–50, Turkey 2017–2024, all with complications); Clinicians n=3 (A&E, surgeon, GP)

Recruitment: Patients via social media; clinicians via professional contacts/snowballing.




Figure 1. Recruitment to Interview Procedure

Data collection: MS Teams, 30 min, recorded & transcribed

Analysis: Braun & Clarke thematic analysis → 4 themes

RESULTS

Harm & Psychological Impact

All patients experienced acute complications such as leaks, sepsis, strictures, and splenic injury. Four reported ongoing physical issues years later. The emotional toll included fear, regret, and social isolation.

“I was sent straight to resus... I was dying.” -Patient E

Compromised Autonomy

Patient choices were shaped by long NHS waiting lists, strict eligibility criteria, high UK private costs, and influence from peers/social media. Several reported booking within weeks, often without thorough consideration. The average price paid was **£2,480**

“I actually said ‘no, stop, I don’t want this done’... but they sedated me anyway and brought me down. They ignored me completely.” - Patient A

Informed Consent & Misaligned Expectations

Pre-operative communication was minimal, with language barriers and poor translation limiting understanding. Several patients misunderstood procedure type or permanence. Risk explanations were brief or absent. All patients felt under informed.

“I signed papers in Turkish. I thought they knew what they were doing.”-Patient C

Justice & Resource Allocation

The NHS aftercare costs as patients face weeks in hospital and multiple surgeries – leading to rising ethical tensions over fairness and resource use.

“These cases stay with us for weeks... huge strain on resources.” – Physician B


DISCUSSION

Autonomy: Patients’ choices were limited by persuasive marketing, selective success stories, financial incentives, rushed booking, and language barriers.

Non-maleficence: Safety was compromised by variable standards, minimal regulation, and poor follow-up, leaving patients vulnerable to serious complications.

Justice: 4/5 patients were female, already barriers in accessing care, increases existing burden on NHS

Strengths	Limitation
First UK-based qualitative study with both patient and clinician perspectives.	Small sample (n=8) limits generalisability.
In-depth narratives on an under-researched issue.	Potential recall bias.



CONCLUSION

Bariatric tourism raises complex ethical concerns that extend beyond individual choice

Findings support:

Enhanced patient education.

Ethical policy reform.

International regulatory oversight

CONTACT INFORMATION

Email: hlqshewr@liverpool.ac.uk

07702903268

REFERENCES



A28. SASI Bypass Is Comparable to OAGB for Weight Loss and Metabolic Outcomes: Evidence from a Systematic Review and Meta-Analysis

M Barghash¹, **M Elfakharany**², Y Badie³, M Riad⁴, O Selim⁵, M Elatrosh⁵, O Ahmed⁶, K Mohamed⁵, A Othman⁷, M Elshaeear⁸, T Sprenger⁹, F Gebauer¹⁰, A Abdelsamad^{10, 11}

¹ North Manchester Hospital, Manchester University Foundation Trust, UK; ² Leeds Teaching Hospitals NHS Trust, Health Education England – Yorkshire and the Humber, UK; ³ Alexandria University, Egypt; ⁴ Assiut University, Egypt; ⁵ Cairo University, Egypt; ⁶ Ain Shams University, Egypt; ⁷ Ashford & St. Peter's Hospitals NHS Trust, UK; ⁸ University of Virginia, USA; ⁹ Knappschaft-Hospital, Recklinghausen, Germany; ¹⁰ University of Witten/Herdecke, Department of Surgery II, Germany; ¹¹ Knappschaft Vest-Hospital, Recklinghausen, Germany.

INTRODUCTION


The global obesity epidemic has driven a steady rise in bariatric surgery, with single-anastomosis procedures such as one-anastomosis gastric bypass (OAGB) and single-anastomosis sleeve ileal bypass (SASI-S) gaining popularity

AIM

This is a systematic review and meta-analysis that aims to compare single-anastomosis Sleeve-ileal (SASI) bypass and one-anastomosis gastric bypass (OAGB) for patients suffering from morbid obesity in terms of safety and efficacy.

METHOD

- . We searched The major databases for studies comparing SASI and OAGB in adults with obesity
- . The primary outcomes were total Weight Loss (%TWL), Excess Weight Loss (%EWL), Excess Body Mass Index Loss (%EBMIL) and changes in the Body Mass Index at 6, 12, and 24 months.
- . Secondary outcomes included the effect on Type 2 Diabetes, Hypertension, Gastro-Oesophageal reflux disease, nutritional indices and complications.
- . Risk of Bias was assessed using Newcastle-Ottawa Scale for cohort studies and RoB-2 for randomised trials.



RESULTS


.Fifteen studies (n=1284) met the inclusion criteria.

.There was no statistically significant difference between the two procedures in relation to the weight loss parameters {%TWL (P=0.75 at 6 months; P=0.91 at 12 months), %EWL (P=0.81 at 6m; P=0.61 at 12m), and BMI change (P=0.57 at 6 m; P=0.30 at 12m)}.


.Other parameters such as remission of T2DM (P=0.35), hypertension (P=0.32), dyslipidaemia (P=0.44), obstructive sleep apnoea (P=0.21), and GORD (P=0.87) were not significantly different.

.Nutritional indices at 1 year (calcium P=0.86; vitamin D P=0.53; vitamin B12 P=0.29; albumin P=0.59) were comparable.


.Operative time (P=0.75), intraoperative complications (P=0.85), overall post-operative complications (P=0.96), and gastrointestinal complications (P=0.18) also showed no significant differences.



12 months %TWL



T2DM remission



Operative time

CONCLUSIONS

SASI bypass is comparable to OAGB in terms of short- to mid-term outcomes related to weight loss, metabolic disease remission, and safety. Procedure choice may therefore be individualised according to patient profile and surgeon expertise. Longer-term comparative studies are warranted to clarify the durability and long-term adverse events.

REFERENCES

- 1-Welbourn R, **et al.** *Obes Surg.* 2019;29(3):782–795.
- 2-Rodrigues de Oliveira Filho J, **et al.** *Surg Obes Relat Dis.* 2025.
- 3-DerSimonian R, Laird N. *Control Clin Trials.* 1986;7(3):177–188.
- 4-Sterne JAC, **et al.** *BMJ.* 2019;366:l4898.
- 5-Shea BJ, **et al.** *BMJ.* 2017;358:j4008.
- 6-McGrath S, **et al.** *Biometrical J.* 2020;62(1):69–98.
- 7-Kermansaravi M, **et al.** *Obes Surg.* 2024;34(6):2054–2065.
- 8-Ataya K, **et al.** *Obes Surg.* 2024;34(9):3285–3297.
- 9-Pipek LZ, **et al.** *Sci Rep.* 2024;14(1):57724-5.
- 10-Hussain A, **et al.** *Int J Surg.* 2019;69:13–18.
- 11-Hsu KF, **et al.** *Obes Surg.* 2023;33(4):1318–1322.
- 12-Yu H, **et al.** *Sci Rep.* 2024;14(1):54949-2.
- 13-Mulla CM, **et al.** *Ann N Y Acad Sci.* 2018;1411(1):53–64

CONTACT INFORMATION

Presenting & Corresponding : Mohamed Elfakharany (Leeds Teaching Hospitals NHS Trust ; HEE – Yorkshire and The Humber, UK)

Email Address : mohamed.elfakharany@nhs.net

H.C. KIM¹, L. HAMIDI², A. MAJUMDAR^{1,3}, M. FEHERVARI^{4,5}, E.R. MCGLONE⁴

¹Department of Metabolism, Digestion and Reproduction, Imperial College London, ²London North West University Healthcare NHS Trust,

³Dept of Health Studies, Royal Holloway University of London, ⁴Department of Surgery and Cancer, Imperial College London, ⁵Department of Bariatric Surgery, Maidstone and Tunbridge Wells NHS Trust

INTRODUCTION

Glucagon decreases lipid accumulation in the liver, but resistance to its actions has been reported in people with obesity and metabolic-associated steatotic liver disease (MASLD). Fasting plasma glucagon is a biomarker of glucagon resistance, but its response to weight loss remains unclear.




Figure 1 A: the liver- α -cell axis in the healthy liver B: glucagon resistance in the steatotic liver.

AIM

To evaluate 1/ if weight loss is associated with a decrease in fasting glucagon in individuals with obesity and 2/ if any association differs between surgical, dietary, and pharmacological interventions.

METHOD

A comprehensive search of MEDLINE and Embase databases yielded 3869 studies that were independently screened by two reviewers.

- Inclusion criteria:** RCTs, interventional, and cohort studies reporting fasting plasma glucagon levels before and after weight loss. Participants were aged ≥ 12 years with a BMI > 25 kg/m². Interventions (dietary, pharmacological or surgical) had to last at least 4 weeks and achieve mean $\geq 5\%$ body weight loss.
- Data Analysis:** Meta-analysis was performed with random-effects model and outcomes were summarized as mean weighted difference with 95% confidence intervals (CI).
- Quality Assessment:** Risk of bias was assessed using validated scoring systems RoB2 and MINORS for RCTs and non-randomized studies respectively.

RESULTS

- Forty-seven studies reported on fasting plasma glucagon, comprising 69 intervention arms (41 surgical, 14 dietary, 14 pharmacological) and 2,061 participants (Fig. 2).
- Mean weight loss across all interventions was -18.23 kg (95% CI: $[-20.20, -16.27]$) (Fig. 3A)**
- This was associated with a reduction in fasting plasma glucagon: -4.05 pmol/L (95% CI: $[-4.50, -3.60]$) (Fig. 3B)**
- When interventions were grouped by type, mean change in glucagon differed:** surgical -3.9 pmol/L (95% CI: $[-5.48, -2.22]$), dietary -2.9 pmol/L (95% CI: $[-4.20, -1.54]$), pharmacological -5.3 pmol/L (95% CI: $[-9.85, -0.78]$).
- There was a correlation between weight loss and reduction in fasting glucagon overall ($r=0.33$, $p=0.006$); strongest for dietary ($r=0.89$, $p<0.0001$), moderate for surgical ($r=0.40$, $p=0.0091$), not significant for pharmacological interventions ($r=0.20$, $p=0.48$).**
- Risk of bias was generally low to moderate for RCTs and moderate for non-randomised studies.




Figure 2. Flow diagram of study selection




Figure 3. Forest plots presenting meta-analysis of mean weighted difference with 95% confidence intervals (CI) for changes in **A:** absolute body weight (kg) and **B:** fasting plasma glucagon (pmol/L) across all intervention arms ($n = 69$). *DL= DerSimonian-Laird random-effects meta-analysis*

CONCLUSIONS

- Weight loss was associated with significant reduction in fasting glucagon.
- Reductions were observed across surgical, dietary, and pharmacological weight loss interventions.
- These findings suggest that hepatic glucagon sensitivity could be at least partially restored through weight reduction. The dose-dependent relationship observed in dietary and surgical interventions further supports the importance of achieving clinically meaningful weight reduction to improve metabolic outcomes.
- Restoring glucagon signalling could be a promising therapeutic strategy for steatotic liver disease.

REFERENCES

- McGlone, E.R., Bloom, S.R. & Tan, T.M.-M. (2024). Glucagon resistance and metabolic-associated steatotic liver disease: A review of the evidence. Journal of Endocrinology. doi:10.1530/joe-23-0365.
- Richter, M.M., Galsgaard, K.D., Elmelund, E., Knop, F.K., Suppli, M.P., Holst, J.J., Winther-Sørensen, M., Kjeldsen, S.A.S. & Wewer Albrechtsen, N.J. (2022) The liver- α -cell axis in health and in disease. Diabetes. 71(9), 1852–1861. doi:10.2337/dbi22-0004.
- Silvestre, M.P., Goode, J.P., Vlaskovsky, P., P., McMahon, C., Tay, A. & Poppitt, S.D. (2018) The role of glucagon in weight loss-mediated metabolic improvement: A systematic review and meta-analysis. Obesity Reviews. 19(2), 233–253. doi:10.1111/obr.12631.

ACKNOWLEDGEMENTS

Louise Levitt, Librarian at the Patricia Bowen Library and Knowledge Service for the Evidence search: Do metabolic surgery and weight-loss by other means decrease surrogate markers of glucagon resistance?. 13th November, 2024. ISLEWORTH, UK: Imperial College NHS and Chelsea & Westminster Hospital NHS Trusts Libraries.

CONTACT INFORMATION

Emma Rose McGlone (e.mcglone@imperial.ac.uk)
Department of Surgery and Cancer, Imperial College London, 7th Floor, Commonwealth Building, Du Cane Road, London W12 0NN, United Kingdom

INTRODUCTION

- Roux-en-Y gastric bypass (RYGB) is widely performed for class III obesity
- Low late-complication burden.
- Gastrojejunal (GJ) anastomotic stricture is one of the long-term complications, typically presenting with progressive dysphagia¹.

AIM

- To understand the clinical problem of gastrojejunostomy (GJ) anastomotic stricture following Roux-en-Y gastric bypass (RYGB).
- To explore the aetiology and underlying pathophysiology contributing to stricture formation and symptom recurrence.
- To review the diagnostic approach, including endoscopic and radiological investigations.
- To evaluate the treatment options, comparing endoscopic balloon dilatation with surgical revision strategies.

CASE REPORT

- 59-year-old male, Roux-en-Y gastric bypass (RYGB) performed in 2018
- Progressive dysphagia to solids and viscous liquids and weight loss
- Ceased smoking one year prior to RYGB
- Demonstrated gastrojejunostomy (GJ) anastomotic stricture with associated ulceration
- Underwent three endoscopic balloon dilatations over an 8-month period
- Only temporary symptom relief after each procedure and weight gain




Figure 1: Endoscopy demonstrating a pinhole stricture in Gastrojejunostomy (GJ) anastomosis

Due to recurrent symptoms, underwent laparoscopic resection of GJ stricture and gastric pouch with:

- Oesophagojejunostomy (OJ) reconstruction
- Hiatus hernia repair

Performed in July 2025




Figure 2. Barium swallow demonstrating a focal narrowing at the anastomotic site, consistent with a stricture (indicated by arrow).

OPERATIVE PROCEDURE

Key operative steps

- Lysis of dense adhesions
- Complete dissection and repair of hiatus hernia
- Resection of the strictured segment
- Reconstruction with OJ anastomosis using 45 mm linear stapler and V-Loc sutures

Postoperative course

- Day 5: Negative Ribena swallow test
- Day 7: Drain removed
- Recovery: Uneventful; discharged in good condition

Follow-up and discharge plan

- Lifelong nutritional supplementation prescribed
- Smoking cessation reinforced
- Scheduled for routine postoperative surveillance and nutritional monitoring

CONCLUSIONS

- Endoscopic dilatation: Effective temporary treatment for short, non-angulated, non-fibrotic benign strictures without ischaemia, leak, or malignancy².
- Limitations: Risk of leak, ulceration, and recurrence³.
- Surgical revision: Indicated after failed dilatations or in cases of severe fibrosis, ulceration, fistula, or abscess⁴.




Figure 3. Intraoperative steps of surgical revision:

- A. Adhesiolysis performed.
- B. Proximal staple to disconnect the pouch from the lower oesophagus.
- C. Staple applied to the gastric remnant due to dense adhesions.
- F. Jejunum divided from the previous alimentary limb to create a new limb.
- G. Vertical stapling of the oesophagojejunostomy (OJ).
- H. Completed OJ anastomosis following enterotomy closure.

REFERENCES

1. Rhodes M, Snyder IC, DeMaria EJ, et al. Gastric pouch and gastrojejunostomy diameter are predictors of weight loss after Roux-en-Y gastric bypass. *Surg Obes Relat Dis.* 2006;2(1):31-35. doi:10.1016/j.soard.2005.10.018-X.
2. Parikh M, Wadhwa A, Hyman N, Ude-Welcome A, Saunders JK, Kurian M, et al. Endoscopic balloon dilation of gastrojejunal anastomotic strictures after laparoscopic gastric bypass: predictors of initial failure. *Surg Obes Relat Dis.* 2011;7(6):714-719. doi:10.1007/s11695-010-0154-7
3. Gill RS, Whitlock KA, Mohamed R, Birch DW, Karmali S. Endoscopic treatment options in patients with gastrojejunal anastomosis stricture following Roux-en-Y gastric bypass. *Gastroenterol Res.* 2012;5(1):1-5. DOI:10.4021/gr385w
4. Cusati D, Sarr M, Kendrick M, Que F, Swain JM. Refractory strictures after Roux-en-Y gastric bypass: operative management. *Surgery for Obesity and Related Diseases.* 2011;7(2):165-169. doi:10.1016/j.soard.2010.11.003

INTRODUCTION

Iron deficiency anaemia (IDA) is a common complication following bariatric surgery.

Changes in gastrointestinal anatomy impair iron absorption and although prophylactic supplementation is widely recommended, adherence remains suboptimal (1, 2).

AIM

This review evaluated reported adherence to iron supplementation and related challenges.

METHOD

We searched PubMed, EBSCO and Cochrane Library for studies published:

- Between 2010 and 2025.
- Included studies focused on adult populations and reported both the rates of IDA and the adherence to iron supplement.
- We excluded case reports, studies with fewer than 10 participants, and those that did not provide data on IDA.

We collected information on the frequency of iron deficiency, patient adherence to supplement recommendations, the types and doses of supplements used and the primary clinical outcomes.

RESULTS

Nine studies met the inclusion criteria and included patients had undergone different types of bariatric surgery. Reported rates of iron deficiency ranged from 6% to 34%, with men showing the highest prevalence. The variation between studies likely reflects differences in surgical methods, follow-up care and adherence rates.

In one study, ferrous sulfate and heme-iron polypeptide were found to be equally effective in the short term, with about 94–95% of patients showing improvement after eight weeks. This suggests that either option can be used effectively to correct iron deficiency soon after surgery. Adherence to iron supplementation varied widely. Of the 340 patients assessed, 37.6% took their supplements regularly, while 23.6% did not take them at all. Those who maintained over 90% adherence had much better iron levels, whereas those who were inconsistent had more than twice the risk of iron deficiency.

The main reasons for skipping supplements were pill burden, gastrointestinal side effects, and difficulty maintaining a daily routine. These findings highlight how important it is to support patients with practical strategies to improve adherence—such as simplifying regimens, managing side effects, and emphasizing the long-term benefits of supplementation.

CONCLUSIONS

Persistent iron deficiency after bariatric surgery can often be linked to poor adherence to supplementation.

To overcome this, we need improved tools for measuring adherence, improved patient education and personalised supplementation plans. Future research should focus on new formulations, better delivery options and practical strategies such as behavioural and educational support.

REFERENCES

1. Ruz M, Carrasco F, Rojas P, Codoceo J, Inostroza J, Rebolledo A, et al. Iron absorption and iron status are reduced after Roux-en-Y gastric bypass. Am J Clin Nutr. 2009 Sep;90(3):527–32.
2. Spetz K, Svedjeholm S, Roos S, Grehn S, Olbers T, Andersson E. Adherence to vitamin and mineral supplementation after bariatric surgery - A two-year cohort study. Obes Res Clin Pract. 2022;16(5):407–12.
3. Lunatta. Image of hand holding pills [Internet]. Shutterstock; [cited 2025 Nov 3]. Available from: <https://www.shutterstock.com>
4. Sage Bariatric. Sleeve Gastrectomy [Internet]. San Antonio (TX): Sage Bariatric Institute; [cited 2025 Nov 3]. Available from: <https://sagebariatric.com/about-surgery-home/sleeve-gastrectomy>



Image source: Lunatta / Shutterstock.com (3)




Image source: Sage Bariatric. Sleeve Gastrectomy (4)

ACKNOWLEDGEMENTS

Luton and Dunstable hospital
Organising committee of LIBSS

CONTACT INFORMATION

Ece Aksu (FY2) in East of England deanery
ece.aksu@nhs.net

1. King's College London, London, UK
2. Lewisham and Greenwich NHS Trust, London, UK
3. Homerton University Hospital, London, UK

INTRODUCTION

- Up to 22% of bariatric surgery (BS) candidates present with current trauma symptoms or diagnoses (active trauma), such as post-traumatic stress disorder (PTSD)^{1,2}.
- While many patients benefit from BS, some show suboptimal weight loss or substantial weight regain³.
- Evidence suggests that trauma may be linked to suboptimal postoperative results^{4,5}.
- Investigating active trauma on BS outcomes can help identify individuals who may be at greater risk of suboptimal results and/or may benefit from additional psychological support.

AIMS

- 01 How do pre-surgical active trauma symptoms/diagnoses influence post-surgical weight loss over time in BS patients?
- 02 How do pre-surgical active trauma symptoms/diagnoses influence post-surgical psychosocial functioning or psychopathology over time in BS patients?
- 03 What is the trajectory of active trauma symptoms over time in BS patients?

METHODS

A protocol was registered prospectively on PROSPERO (CRD42024523258) in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement⁶

PECOS⁷ inclusion criteria

POPULATION

All adults (≥18 years) who have undergone BS

EXPOSURE

- PTSD; acute stress disorder; complex PTSD (C-PTSD); prolonged grief disorder; adjustment disorder
- Borderline personality disorder (BPD)/emotionally unstable personality disorder

COMPARATOR

Pre-surgery vs post-surgery (within-subjects design)

OUTCOMES

- Weight loss-related outcomes
- Psychosocial and/or psychopathological outcomes

STUDY DESIGN

Any quantitative design

Electronic databases searched:

(1) MEDLINE; (2) EMBASE; (3) PsycINFO; (4) CINAHL; (5) Web of Science

Grey literature sources:

(1) HMIC database; (2) SSRN; (3) PsycEXTRA; (4) EThOS; (5) WorldCat OCLC


Risk of bias: The Newcastle-Ottawa Scale (NOS)⁸

- Authors SH/SQM used NOS to examine methodological quality across three domains: selection, comparability, and ascertainment of outcome
- Studies were rated as poor, fair or high quality

A39. The impact of psychological trauma on weight loss, psychosocial functioning, and psychopathology in bariatric and metabolic surgery candidates: a systematic review.

S. Hollyfield^{1,2}, W. Scott¹, P. Schmill¹, S. Quirke-McFarlane³, R. Mamidanna², E. McBride^{1,2}

RESULTS



Study characteristics

Study Designs: 12 longitudinal studies (7 prospective, 5 retrospective)

Participants: Total N = 5,543 (32-2,373); Age range= 38–53 years

Procedures: Roux-en-Y Gastric Bypass, Laparoscopic Adjustable Gastric Band, and Sleeve Gastrectomy

Outcomes: BMI (n=5), %EWL (n=3), PTSD (n=7), BPD (n=3), Adjustment disorders (n=2)

Follow-up: Range = 6–84 months (M = 28.23, SD = 19.26)

Methodological quality




Poor study quality: n=8 | Fair study quality: n=4


- Non-representative samples of the exposure cohort (n=12)
- Inadequate follow-up procedures (n=9)
- Failure to control for key confounders (n=9)

Key findings

1. Weight-Related Outcomes (n=8)⁹⁻¹⁶



- PTSD showed no significant effect on post-surgical weight loss
- One study found that a previous adjustment disorder predicted greater weight loss
- Results for BPD were mixed with small, imprecise effects



2. Psychological Outcomes (n=2)^{11,15}



- One study found that PTSD was strongly associated with other Axis I diagnoses
- One study found that PTSD was significantly associated with poorer mental health-related quality of life

3. Trauma Symptom Trajectories (n=5)^{11,17-20}



- Only two studies provided statistical comparisons
- No significant symptom reduction was observed across studies

CONCLUSIONS




Methodological considerations

Overall, poor study quality

Measurement Issues:

- Widespread use of outdated assessment tools lacking alignment with diagnostic manuals
- Inconsistent outcome reporting

Sample Bias: Predominantly white and privately insured sample → not



Review strengths and limitations

- Comprehensive search strategy
- Inclusion of two diagnostic manuals^{20,21} definitions of trauma-related disorders
- Incorporation of BPD given symptom overlap with C-PTSD


Substantial methodological heterogeneity:

- Restricted comparability across studies
- Precluded meta-analysis
- Limits the precision of findings



Clinical Implications

- Current evidence is insufficient for evidence-based clinical guidelines.
- Active trauma may co-occur with other psychiatric disorders → comprehensive screening
- Well-designed longitudinal studies with robust retention strategies
- Representative samples and standardised assessment tools.
- Mediation models to identify causal mechanisms



Future research




Conclusions

- A paucity of high-quality research in this area
- Substantial methodological heterogeneity limits firm conclusions
- Future research is needed, employing standardised, validated measures of trauma, robust designs, and long-term follow-up at standardised timepoints

REFERENCES

SCAN FOR REFERENCE LIST



CONTACT INFORMATION

Corresponding Author: Shakira Hollyfield

PhD Candidate & Trainee Health Psychologist

shakira.hollyfield@kcl.ac.uk



A41. Modern Medicine and Safe Sleeve Gastrectomy: Strategies in Patients who Refuse Blood Product

Authors: M. Gogol^{1,2} MD, T.Singh¹, S.S.Naik¹, M. Silagava¹ MD, G. Zurabashvili² MD, B. Arabulil² MD, K.Sakhechidze² MD, PhD, M.Chubinidze² MD, G.Kupradze² MD, Kh Kaladze¹ Md, PhD.

1.Grigol Robakidze University (GRUNI) 3 Irina Enukidze Street, Tbilisi, 01

2. American Hospital Tbilisi 17 Ushangi Chkheidze Street, Tbilisi, 0102 Ge




INTRODUCTION

Sleeve gastrectomy is currently the most common bariatric surgery and is effective for long-term weight loss. However, it carries a bleeding risk of 0.4–4%. For patients who decline blood transfusions, such as Jehovah's Witnesses, this risk poses unique clinical and ethical challenges.

AIM

To explore strategies that allow sleeve gastrectomy to be performed safely without the need for blood transfusion.

Jehovah's Witnesses Population Distribution




1

METHOD

A review of the literature on transfusion-free bariatric surgery was conducted, focusing on approaches used before, during, and after surgery to reduce the risk of bleeding.

The impact of prehospital tranexamic acid on mortality and transfusion requirements



The impact of prehospital tranexamic acid on mortality and transfusion requirements: match-pair analysis from the nationwide German TraumaRegister DGU® | Critical Care | Full Text | Visit


RESULTS

Preoperative optimization with intravenous iron, erythropoietin, and correction of vitamin deficiencies helped increase hemoglobin levels. During surgery, the use of minimally invasive techniques, meticulous control of bleeding with advanced energy devices, staple-line reinforcement, and prophylactic tranexamic acid were effective in limiting blood loss. Postoperatively, careful hemoglobin monitoring, continuation of antifibrinolytics, and early mobilization further supported recovery. Case series (sample sizes between 22–35 patients) reported no mortality, low complication rates ($\leq 4.5\%$), and hospital stays similar to those seen in patients who did not refuse transfusion.



Intervention	Dose/Timing	Outcome
IV Iron	1000 mg, 1-2 weeks pre-op	↑ Hemoglobin by 1-2 g/dL
Erythropoietin	40,000 IU/week, 2-4 weeks pre-op	↑ Red blood cell count
Vitamin B12/Folate	1000 mcg/day if deficient	Supports hematopoiesis

Post-Operative Approach



CONCLUSIONS:


With possibilities of modern medicine, careful planning and structured “bloodless” surgical protocols, sleeve gastrectomy can be performed safely in patients who refuse blood products. Future studies and standardized guidelines are needed to confirm and broaden these findings

REFERENCES

1”Enhancing bariatric surgery safety for patients refusing blood transfusions: a specialized protocol with comprehensive technical measures”. Citation: Dalkılıç MS, Gençtürk M, Şişik A, Erdem H. Updates In Surg. 2024;76(6):2489-2494. doi:10.1007/s13304-024-01894-8. PMC. 2.”Effectiveness of prophylactic doses of tranexamic acid in reducing hemorrhagic events in sleeve gastrectomy” Citation:. Lech P, Michalik M, Waczyński K, Osowiecka K, Dowgiałło-Gornowicz N. Langenbecks Arch Surg. 2022;407(7):2937-2943. Springer. 3.”How to approach major surgery where patients refuse blood transfusion (including Jehovah's Witnesses)”. Citation: Gohel MS, Bulbulia RA, Slim FJ, Poskitt KR, Whyman MR. Ann R Coll Surg Engl. 2005;87(1):3-14. PMC.

CONTACT INFORMATION

mananagogol@[mimatbilisi.com](mailto:mananagogol@mimatbilisi.com)
www.mimatbilisi.com



ACKNOWLEDGEMENTS

I Would like to express my deep gratitude to Professor Mamuka Tavkhelidze, Professor David Jikia,, Professor Andrew A. Gumbs, Doctor Moammed Said Dalkilic, Doctor Khvicha Khajavelidze, Doctor Yameen Khan, Doctor Nina Inauri, Giorgi Beria and Berdia Kunelauri for inspiration, collaboration and support.

Special gratitude to GRUNI, SSII, XNY Medical, GLR Georgia; HP Fund and Medea International Medical Association MIMA for making this participation possible.

I. LEE¹, J. KIM¹, Y. KWON¹, J. MIN¹, and S. PARK¹¹ Department of Foregut Surgery, Korea University College of Medicine, Seoul, South Korea

INTRODUCTION

- Metabolic and bariatric surgery (MBS) has traditionally been restricted to BMI ≥ 35 kg/m²
- Recent guidelines support extending eligibility to class I obesity (BMI 30-34.9 kg/m²)
- Evidence directly comparing outcomes between low- and high-BMI obese cohorts remains limited

AIM

To evaluate the efficacy of laparoscopic sleeve gastrectomy (LSG) in patients with class I obesity (BMI 30-34.9 kg/m²) compared to higher BMI patients (class II-III obesity, BMI 35-50 kg/m²), focusing on weight loss and metabolic disease improvements.

METHOD

Study design


- Retrospective analysis of obese patients who underwent LSG at a tertiary hospital in South Korea from 2019 to 2023

Patient groups

- Class I obesity: BMI 30-34.9 kg/m² (n = 18)
- Class II-III obesity: BMI 35-50 kg/m² (n = 67)

Outcomes evaluated


- Weight loss results (%TWL, %EWL)
- Metabolic disease improvements at baseline, and postoperative 6 and 12 months



RESULTS

Table 1. Baseline characteristics

Variable	Class I	Class II-III	p-value
Age (years)	45.7 ± 10.6	36.8 ± 11.5	0.004
Sex (% Female)	77.8%	55.2%	0.143
Weight (kg)	87.6 ± 10.0	117.0 ± 17.8	<0.001**
BMI (kg/m ²)	32.8 ± 1.6	41.5 ± 4.1	<0.001**
Type 2 DM (%)	61.1%	34.3%	0.074
Hypertension (%)	44.4%	76.1%	0.021*
Dyslipidemia (%)	61.1%	49.3%	0.530



CONCLUSIONS

Comparable weight loss: Class I obesity patients achieved similar %TWL to class II-III, with superior %EWL outcomes

Excellent metabolic outcomes: both groups showed significant improvements in glycemic control (HbA1c and FBS) at postoperative 6- and 12-months

Differential benefits: Class I patients had better hypertension control, while class II-III patients showed higher diabetes medication discontinuation

Clinical implication: LSG is effective and safe for class I obesity, supporting expanded bariatric surgery indications to BMI 30-34.9 kg/m²

Table 2. Changes in anthropometric measurements at 6-month and 1-year post-surgery.

Obesity Class	Baseline			6 months			1 year		
	I	II-III	p-value	I	II-III	p-value	I	II-III	p-value
%TWL	-	-	-	23.7 ± 5.5	23.5 ± 6.8	0.918	26.6 ± 6.8	28.8 ± 8.7	0.252
%EWL	-	-	-	66.7 ± 14.1	50.2 ± 14.8	<0.001**	74.7 ± 17.7	61.1 ± 18.0	0.008**
BW (kg)	87.6 ± 10.0	117.0 ± 17.8	<0.001**	66.7 ± 7.7	89.2 ± 13.8	<0.001**	64.0 ± 6.8	82.7 ± 12.8	<0.001**
BMI (kg/m ²)	32.8 ± 1.6	41.5 ± 4.1	<0.001**	25.0 ± 1.7	31.7 ± 3.7	<0.001	24.0 ± 1.9	29.4 ± 3.6	<0.001
WC (cm)	108.8 ± 7.3	127.6 ± 13.7	<0.001**	66.7 ± 7.7	89.2 ± 13.8	<0.001	64.0 ± 6.8	82.7 ± 12.8	<0.001

Table 3. Patients taking medications for metabolic diseases (DM, HTN, and DL) and prevalence of metabolic syndrome at 6-month and 1-year post-surgery.

Obesity Class	Baseline			Postoperative 6 months			Postoperative 1 year		
	I	II-III	p-value	I	II-III	p-value	I	II-III	p-value
T2DM (n, %)	11 (61.1)	23 (34.3)	0.074	7 (38.9)	10 (15.2)	0.044*	7 (38.9)	8 (12.1)	0.015*
HTN (n, %)	8 (44.4)	51 (76.1)	0.021*	2 (11.1)	29 (43.3)	0.025*	1 (5.6)	23 (34.3)	0.035*
DL (n, %)	11 (61.1)	33 (49.3)	0.530	4 (22.2)	20 (30.3)	0.705	6 (33.3)	19 (28.8)	0.934
MS (n, %)	16 (88.9)	58 (86.6)	1.000	6 (33.3)	25 (37.3)	0.972	6 (33.3)	20 (29.9)	1.000

REFERENCES

- Scully T, Ettela A, LeRoith D, Gallagher EJ. Obesity, Type 2 Diabetes, and Cancer Risk. *Front Oncol.* 2020;10:615375.
- Kim MS, Kim JY, Song YS, Hong S, Won HH, Kim WJ, et al. Association of bariatric surgery with indicated and unintended outcomes: An umbrella review and meta-analysis for risk-benefit assessment. *Obes Rev.* 2024;25(3):e13670.
- Organization WH. Obesity and overweight: World Health Organization; 2024 [updated 1 March 2024. Available from: <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>.
- Eisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery. *Obes Surg.* 2023;33(1):3-14.
- Kermansaravi M, Chiappetta S, Parmar C, Shikora SA, Prager G, LaMasters T, et al. developed by an expert modified Delphi consensus. *Sci Rep.* 2024;14(1):3445.
- De Luca M, Shikora S, Eisenberg D, Angrisani L, Parmar C, Alqahtani A, et al. Sc bariatric surgery (IFSO/ASMBS). *Surg Obes Relat Dis.* 2024;20(11):991-1025.
- Yue Z, Jin Y, Sha H, Wu Q, Li L, Xia Y, et al. The Therapeutic Effectiveness of Lap Kg/m(2)) and the Relationship of BMI to Weight Loss. *Int J Gen Med.* 2024;17:1521

CONTACT INFORMATION

Inyoung Lee, Clinical Assistant Professor, KUMC.
irene.inyoung.lee@gmail.com // (+82)-10-5402-9524



INTRODUCTION

Metabolic syndrome, particularly hypercholesterolemia and hypertriglyceridemia, contributes to the development of a chronic inflammatory process in the liver in the form of nonalcoholic fatty liver disease (NAFLD). The negative consequences of NAFLD include disease progression in the setting of nonalcoholic steatohepatitis (NASH)

AIM

To identify laboratory manifestations of nonalcoholic steatohepatitis in the form of ketonemic syndrome in obese patients after laparoscopic sleeve gastrectomy (LSG).

METHOD

- 1. A total of 257 obese patients who underwent LSG were analyzed.
- 2. Patients were divided into three groups: control — obese without NAFLD (n=94, BMI 39.05±7.1 kg/m²), comparison — obese with nonalcoholic fatty hepatosis (n=83, BMI 42.0 ±7.5 kg/m²), and study — obese with NASH (n=80, BMI 42.4±8.3 kg/m²).
- 3. Assessment included ketone body concentration in exhaled air condensate, blood, and urine, as well as serum γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP) activity

Laboratory findings in non-alcoholic fatty liver disease

DIAGNOSTIC AND PROGNOSIS PARAMETERS	GROUPS OF PATIENTS		
	NORM	NAFLD	NASH
	n=11	n=12	n=19
γ-GTP activity	0,177	0,514	0,937
ALP activity	0,189	0,439	0,877
Ketonuria	0,053	0,497	0,792
Ketone levels in air condensate	0,104	0,428	0,713
Ketonemia	0,012	0,312	0,681




RESULTS

After LSG, all groups demonstrated increased ketone levels, peaking at 1 month postoperatively.


In exhaled condensate, NASH patients showed significantly higher values (68.9±8.91 ppm) compared with controls (21.82±0.09 ppm; p<0.05).

Serum ketone bodies were also elevated in NASH (8.0±1.18 mmol/L vs. 1.48±0.13 mmol/L in controls; p<0.05), while hyperketonuria occurred earlier and more intensively in NASH (2.32±0.49 mmol/L) and fatty hepatosis (1.66±0.22 mmol/L) than in controls (0.57±0.09 mmol/L). Importantly, normalization of ketone levels by 6 months was observed only in controls, whereas in NASH patients hyperketonemia persisted.

GGT and ALP activities increased 1.4-fold in NASH patients and remained elevated up to 10 months, indicating prolonged hepatic stress and intensified lipolytic processes.




COMPARATIVE DYNAMICS OF CHANGES IN THE LEVEL OF KETOSIS IN EXHALED AIR CONDENSATE (ppm)



COMPARATIVE DYNAMICS OF CHANGES IN THE LEVEL OF KETONEMIA (mmol/l)

LABORATORY CRITERIA FOR THE PROBABILITY OF THE DEGREE OF ACTIVE MANIFESTATION OF NASH IN THE FORM OF KETONEMIC SYNDROME AFTER BARIATRIC SURGERY					
DEGREE OF PROBABILITY	LABORATORY CRITERIA			Activity in the blood	
	Ketosis level				
	Exhalation (ppm)	Blood (mmol/L)	Urine (mmol/l)	γ-GT (U/L)	ALP (U/L)
Absent	≤0,4	≤0,4	≤0,4	≤70	≤120
Low	0,5-14,9	0,41-0,99	0,41-0,8	71-90	121-140
High	15≤	1,0≤	0,81≤	91≤	141≤



CONCLUSIONS

NASH in obese patients after LSG is characterized by sustained hyperketonemia, hyperketonuria, and elevated ketone concentrations in exhaled air, accompanied by prolonged elevation of GGT and ALP. These findings highlight ketonemic syndrome as a key laboratory marker of hepatic functional alterations in the early and intermediate postoperative period after LSG.

REFERENCES

Polyzos SA, Kountouras J, Zavos C, et al. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2020;12:365–383.

Rutkowski JM, Davis KE, Scherer PE. Mechanisms of obesity and related pathologies: the macro- and microcirculation of adipose tissue. FEBS J 2019;276:5738 –5746.

Enomoto N, Takei Y, Yamashima S, et al. Protective effect of pioglitazone against endotoxin-induced liver injury through pre-vention of Kupffer cell sensitization. Alcohol Clin Exp Res 2015; 29:216S–219S.

ACKNOWLEDGEMENTS

We would like to thank the IFSO and LIBSS organizations for the developed treatment methods, clinical guidelines, and the opportunity to participate in sharing such valuable information based on the results of our research.

CONTACT INFORMATION

100109, Uzbekistan, Tashkent, st. Farabiy 2
doctoroybek84@gmail.com
+998903713400 (tel., WhatsApp)

INTRODUCTION

Sleeve gastrectomy (SG) is the most frequently performed bariatric procedure worldwide [1,2]. While outcomes are well documented, the role of hormonal differences—especially between reproductive-age and postmenopausal women—remains underexplored [3].

Age-related changes in estrogen levels, insulin sensitivity, and fat distribution may influence metabolic response after surgery [4,5]. However, most studies have not stratified patients by menopausal status. Understanding whether hormonal background affects postoperative weight loss could improve patient counseling and outcome expectations.

AIM

This study aims to compare total weight loss (%TWL) and excess weight loss (%EWL) between reproductive-age and postmenopausal female patients one year after sleeve gastrectomy, and to evaluate whether hormonal status influences weight loss outcomes.

METHOD

- We retrospectively analyzed female patients who underwent sleeve gastrectomy between 2019 and 2024. Patients were grouped as reproductive (≤ 45 years) and postmenopausal (> 45 years).
- Demographics (age, BMI, height, weight) and weight loss outcomes at 12 months were compared. %TWL and %EWL were calculated using standard formulas.
- Group comparisons were performed using independent t-tests. Statistical significance was defined as $p < 0.05$.

Y.YAPALAK¹, A.SIRINOC AK²

1 Uskudar University, Istanbul, Turkey

2 Private Sancaktepe Bolge Hospital, Istanbul, Turkey




RESULTS

A total of 702 patients were in the reproductive group and 173 in the postmenopausal group. Mean age was 33.6 ± 6.2 and 51.5 ± 4.8 years, respectively. Both groups achieved substantial weight loss at 1 year:

- %TWL: 66.2% (reproductive) vs 69.1% (postmenopausal), $p = 0.455$

- %EWL: 192.8% (reproductive) vs 208.2% (postmenopausal), $p = 0.293$

Although postmenopausal patients had slightly higher weight loss outcomes, the differences were not statistically significant.



CONCLUSIONS

Menopausal status does not appear to significantly alter the effectiveness of sleeve gastrectomy in terms of short-term weight loss. Although postmenopausal women showed marginally greater outcomes, these differences were not statistically significant.

These findings support the notion that hormonal background alone should not influence surgical candidacy. Future studies should explore long-term metabolic, hormonal, and quality-of-life outcomes in distinct female age groups to better understand the interaction between bariatric surgery and endocrine changes throughout the female lifespan.

REFERENCES

- Mechanick JI, Apovian CM, Brethauer S, et al. Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures – 2013 Update. Obesity (Silver Spring). 2013;21(S1):S1–S27.
- Angrisani L, Santonicola A, Iovino P, et al. Bariatric Surgery Worldwide 2013. Obes Surg. 2015;25(10):1822–32.
- Mechanick JI, Youdim A, Jones DB, et al. Clinical Practice Guidelines for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Surgery Patient. Surg Obes Relat Dis. 2008;4(Suppl 5):S109–84.
- Lee WJ, Almulaifi A, Tsou JJ, et al. Laparoscopic Sleeve Gastrectomy—The First 300 Cases: Short-Term Outcomes and Technical Considerations. Obes Surg. 2014;24:23–9.
- Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: A systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107(10):1755–67.

ACKNOWLEDGEMENTS

We thank the Clinichub Obesity Treatment Team and the staff of İstanbul Sancaktepe Bölge Hospital for their support in patient care and data collection.

CONTACT INFORMATION

Yunus Yapalak, MD, General & Bariatric Surgeon
Email: yunusyapalak@gmail.com
ORCID: <https://orcid.org/0000-0002-0832-1859>
Instagram: @dryunusyapalak

A46: Unexpected Chemical Pathology Leading to Excess Weight Regain Post-Bariatric Surgery

A. MUDGAL¹, S. SANHOTRA², M. SHARMA³, S. AGRAWAL⁴

1 King's College, London, United Kingdom, 2 Bart's and the London School of Medicine, United Kingdom, 3 Homerton University Hospital, London, United Kingdom, 4 Homerton University Hospital, London, United Kingdom

INTRODUCTION

Primary Ovarian Failure (POI) is ovarian defect which encompasses both primary amenorrhoea and secondary amenorrhea. The latter is due to the premature depletion of ovarian follicles before the age of 40 years. [1]

It often presents with fatigue and bone and musculoskeletal pain due to reduced oestrogen signalling [1][2]. Menopausal changes in the hormonal milieu are additionally associated with an increase in total body and abdominal fat [3].

As contraceptive methods such as the progesterone based Mirena Coil and 'mini-pill' can cause oligomenorrhoea or amenorrhea, they can make POI harder to diagnose. [4] This can complicate the management of post-bariatric surgery patients, as seen in this case of a patient presenting with refractory multi-morbidities and associated weight regain post-surgery.

RESULTS

A 28-year-old African-Caribbean lady presented with excess weight regain, fatigue, bloating, hip arthralgia and plantar fasciitis 8 years post Roux-en-Y Gastric bypass surgery. Her pre-surgery BMI was 39kg/m² (96kg), and the patient had lost more than 45% excess weight in 2 years post-surgery (61.4kg) but had now started regaining this. She had reached a current weight of 86kg, despite being diligent with her dietary and lifestyle modifications post-surgery. Coeliac disease was ruled out, and patient was found to have SIBO which failed to respond to treatment with Doxycycline. The patient was also treated for vitamin D deficiency and secondary hyperparathyroidism. However, despite these treatments, her musculoskeletal pains persisted, continuing to significantly limit her mobility and thus ability to lose weight.

Utilising an MDT approach, it was evaluation of her gynaecological history which provided a breakthrough in this case. The patient had an in situ Mirena coil for the past several years and therefore no regular bleeding. However, she had recently reported loss of her normal, cyclical, pre-menstrual symptoms such as Mittelschmerz pain and mastalgia. Upon investigation, her FSH, LH, oestradiol and AMH levels were in the menopausal range, despite being in her late 20s, confirming primary ovarian failure (POI). She was referred to gynaecology/fertility and rheumatology clinics and was initiated on HRT, testosterone gel and statins (due to POI related increased CVD risk). Her MSK symptoms finally improved in response to hormonal treatment, improving her tiredness and mobility.

The patient has since been successful in losing weight now, aided by Mounjaro for a brief period, further highlighting the importance role of hormonal therapies and multi-speciality care in preventing excess weight regain post bariatric surgery.

CONCLUSIONS

This case demonstrated that patients with weight regain post bariatric surgery should be extensively investigated and treated for any other new medical pathologies using a multidisciplinary approach. This can help to maintain bariatric surgery related excess weight loss and its associated health benefits.

Unexplained weight gain in female patients post bariatric surgery should be evaluated for causes other than lifestyle factors. A high-index of suspicion should be maintained for gynaecological causes and even rare conditions such as primary ovarian failure(POI). As contraception can mask these symptoms, we recommend that female patients of all ages have gonadotropins measured if clinically indicated and perimenopausal women have annual monitoring.

REFERENCES

1. Beck-Peccoz P, Persani L. Premature ovarian failure. Orphanet Journal of Rare Diseases. 2006 Apr 6;1(1).
2. Samad N, Nguyen HH, Scott D, Ebeling PR, Milat F. Musculoskeletal Health in Premature Ovarian Insufficiency. Part One: Muscle. Seminars in Reproductive Medicine. 2020 Sep 1;38(04/05):277–88.
3. Davis SR, Castelo-Branco C, Chedraui P, Lumsden MA, Nappi RE, Shah D, et al. Understanding weight gain at menopause. Climacteric: The Journal of the International Menopause Society [Internet]. 2012 Oct 1;15(5):419–29. Available from: <https://pubmed.ncbi.nlm.nih.gov/22978257/>
4. Robinson G. Contraception consultation and assessment for women over 40. Journal of Prescribing Practice. 2023 May 2;5(5):194–203.

ACKNOWLEDGEMENTS

Our deepest appreciation to the patient whose story we have been fortunate to share and the staff at Homerton University Hospital.

CONTACT INFORMATION

Corresponding Author:
Dr Manisha Sharma,
Manisha.sharma2@nhs.net

A. MUDGAL¹, S. SANHOTRA², M. SHARMA³, A. GORALCZYK⁴

1 King's College London GKT School of Medicine, London, United Kingdom, 2 Bart's and the London School of Medicine, United Kingdom, 3 Homerton University Hospital, London, United Kingdom, 4 Homerton University Hospital, London, United Kingdom

INTRODUCTION

Vitamin A is a fat-soluble vitamin being absorbed in the small intestine. It is converted into retinyl palmitate and stored in the liver for two years which can then be later hydrolysed into retinol. Vitamin A is vital for rhodopsin formation from rod and cone opsins which are essential for phototransduction [1].

As bariatric surgery is becoming more popular for morbid obesity, and the long duration of liver stores of vitamin A, there is a risk of delayed diagnosis and treatment of vitamin A deficiency as well as a rise of cases in the developed world. [1][2][3]

Recovery of visual function appears to be rapid following replacement therapy. [2]

CONCLUSIONS

This case report highlights the severe malabsorptive nature of fat-soluble vitamins, especially vitamin A, in duodenal switch surgery patients, and therefore the importance of long-term biochemical monitoring to achieve good surgical outcomes. Additionally, there is a potential need for lifelong, high-dose, parenteral vitamin supplementation after duodenal switch surgery.

Vitamin A deficiency should be a differential in night blindness, especially in the context of bariatric surgery patients.

RESULTS

A 40-year-old Caucasian female presented with a two-year long history of diminished vision in the evening, xanthopsia, paraesthesia and debilitating fatigue, following a laparoscopic sleeve gastrectomy and laparoscopic duodenal switch surgery five and three years ago respectively. The patient was diagnosed with papilledema, night blindness and glove and stocking neuropathy, despite good compliance with oral multivitamin and mineral supplements.

Her indication for surgery was morbid obesity with a body mass index (BMI) of 68.12kg/m², and she had no other medical conditions except for asthma. The patient demonstrated good surgical outcomes, with a 53.1% reduction in body weight four years after her second surgery.

Upon review, she was diagnosed with severe vitamin A deficiency, with a level of less than 0.35µmol/L (normal range 1.05-3.84 µmol/L). Despite treatment with AquADEKs, a fat-soluble preparation of vitamin A, and stepwise increases in dosing up to 40,000 IU oral vitamin A per day, the patient presented 18 months later in A&E with a significantly reduced visual acuity, which had left her wheelchair bound.

Investigations in A&E revealed undetectable blood vitamin A levels, prompting an urgent series of three vitamin A intramuscular injections, a total of 300,000 IU, which resulted in dramatic improvement of vision and detectable levels at 0.49µmol/L.

Therefore, it was concluded that this patient cannot absorb vitamin A orally and will require lifelong parenteral vitamin A administration. Following 4 years of regular vitamin A intramuscular injections, her serum vitamin A levels normalised to 1.30µmol/L, and the patient reported complete resolution of her symptoms.

REFERENCES

- (1)Chae T, Foroozan R. Vitamin A deficiency in patients with a remote history of intestinal surgery. Br JOphthalmol. 2006 Aug;90(8):955-6. doi: 10.1136/bjo.2006.092502.
- (2)Clifford LJ, Turnbull AMJ, Denning AM. Reversible night blindness – A reminder of the increasing importance of vitamin A deficiency in the developed world. J Optom. 2013 Jul;6(3):173–4. doi:10.1016/j.optom.2013.
- (3)Spits Y, De Laey JJ, Leroy BP. Rapid recovery of night blindness due to obesity surgery after vitamin A repletion therapy. Br J Ophthalmol. 2004 Apr;88(4):583-5. doi: 10.1136/bjo.

ACKNOWLEDGEMENTS

Our deepest appreciation to the patient whose story we have been fortunate to share and the staff at Homerton University Hospital.

CONTACT INFORMATION

Corresponding Author:
Dr Manisha Sharma,
Manisha.sharma2@nhs.net

INTRODUCTION

Venous thromboembolism (VTE) is fatal postoperative complication of metabolic and bariatric surgery (MBS) and the leading cause of mortality within the first postoperative 30 days.

Standard prophylactic measures:

- Early postoperative ambulation
- Sequential compression devices (SCDs)
- Chemoprophylaxis with LMWH

However, additional risk factors (sometimes hidden) may incite VTE and necessitate extended anticoagulation therapy.

Hormonal Therapy (HT):

- Includes: Oral contraceptives (OCs), hormone replacement therapy (HRT), and selective estrogen receptor modulators (SERMs)
- Increases coagulation factor activity and impairs fibrinolysis → Prothrombotic state
- Patients on HT undergoing MBS may have increased risk of VTE, especially porto-splenic-mesenteric venous thrombosis (PSMVT), a rare but potentially fatal type of VTE

AIM

To present two cases of VTE following laparoscopic sleeve gastrectomy (LSG) in patients with a history of HT and to discuss optimal thromboprophylaxis strategies with literature review.

METHODS

Study Design:


- Two cases of post-MBS VTE were reviewed
- Focus areas: Clinical presentation, imaging findings, treatment course

Literature Review

- Contextualization of cases within the broader evidence on HT, MBS, and thrombotic risk factors
- Emphasis on optimal DVT prophylaxis strategies

CASE PRESENTATION

Case	#1: M/37	#2: F/30
BMI (kg/m ²)	27.5	24.2
Comorbidity	None	None
Smoking	Current, 10 P-Y	Never
HT history	Estrogen -Duration: 1 month -Discontinued 3 months before MBS	OC pills -Duration: unknown -Discontinued 3 days before MBS
Previous VTE history	None	None
Surgical procedure	LSG	LSG
Perioperative DVT prophylaxis?	Yes, LMWH	No
VTE Symptoms	Fever and left abdominal pain on POD 14	Left lower abdominal pain on POD 10
CT findings	Portal and splenic vein thrombosis without bowel ischemia	Portal, splenic, and superior mesenteric vein thrombosis without bowel ischemia
Intervention	PV mechanical thrombectomy	PV mechanical thrombectomy → Failed
Anticoagulation therapy	Enoxaparin 80 mg BID (7 days) → Rivaroxaban 15 mg BID (11 weeks) (total duration: 3 months)	Enoxaparin 80 mg BID (7 days) → Rivaroxaban 15 mg BID (11 weeks) (total duration: 3 months)
Outcome	Follow-up loss	Follow-up loss



RESULTS & DISCUSSION

Key Findings:

- Both patients presented with delayed postoperative VTE (POD 10-14)
- Resolution with thrombectomy: 1 case; one with medical therapy (subacute-chronic nature)
- Neither developed bowel necrosis nor required additional surgery

VTE Risk Factors in MBS

- Postoperative VTE incidence: ~0.5% (80% occur post-discharge)
- Key risk factors: obesity, surgical stress, smoking, BMI > 60 kg/m², hormonal therapy, past VTE

Thromboprophylaxis Recommendations:

- For all patients: Mechanical prophylaxis, early ambulation, LMWH within 24 hours of MBS
- High-risk patients: Extended prophylaxis
- Those with history of DVT/PE, hypercoagulable state, HT use
- Consider risk calculators (e.g., Capirini Risk Assessment Motel) for post-discharge anticoagulation

CONCLUSIONS

- ✓ Increased risk of VTE in MBS patients on hormonal therapy, particularly with additional risk factors such as smoking
- ✓ Detailed history taking is essential to identify hidden risk factors (e.g., hormonal therapy use)
- ✓ Individualized thromboprophylaxis is critical
- ✓ Extended post-discharge anticoagulation should be considered for high-risk patients
- ✓ Given that 80% of VTE cases following MBS occur post-discharge, routine postoperative surveillance is recommended
- ✓ Early imaging in symptomatic patients may facilitate prompt intervention and prevent severe complications
- ✓ Further prospective studies are needed to establish evidence-based guidelines for thromboprophylaxis in MBS patients with exposure to hormonal therapy

REFERENCES

1. Moon RC, Ghanem M, Teixeira AF, et al. Assessing risk factors, presentation, and management of portomesenteric vein thrombosis after sleeve gastrectomy: a multicenter case-control study. Surg Obes Relat Dis. 2018;14:478-483.
2. Meng M, Pradhan J, Singh A. The association between bariatric surgery and extensive portal vein thrombosis: A case report. Int J Surg Case Rep. 2024;123:110276.
3. Belluzzi A, Sample JW, Marrero K, et al. Rare Complications Following Laparoscopic Sleeve Gastrectomy. J Clin Med. 2024;13:4456.
4. Al Wadaani HA, Al Omar S, AlRaihan J, et al. Post laparoscopic sleeve gastrectomy portal vein thrombosis with venous mesenteric ischemia: a case report with literature review. J Surg Case Rep. 2024;8:rjae462.
5. Thaher O, Wendt E, Hukauf M, Croner RS, Stroh C. Thromboembolic prophylaxis in bariatric and metabolic surgery: state-of-the-art according to the results of a nationwide registry study. Updates Surg. 2025 (in press).
6. Leon S, Rouhi AD, Perez JE, et al. Bariatric surgery in patients with preoperative therapeutic anticoagulation: a 2015-2021 MBSAQIP database study. Surg Obes Relat Dis. 2024;20:1260-1269.
7. Mechanick JL, Apovian C, Brethauer S, et al. Clinical Practice Guidelines For The Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures – 2019 Update. Endocr Pract. 2019;25(Suppl 2):1-75.

CONTACT INFORMATION

Inyoung Lee, Clinical Assistant Professor, KUMC.
irene.inyoung.lee@gmail.com // (+82)-10-5402-9524

Authors: G. PRADIP¹, F. RUBINO¹
¹Kings College Hospital, London, United Kingdom

INTRODUCTION

Obesity is now understood not merely as elevated body mass index (BMI) but as a complex, progressive condition of excess adiposity that may remain sub-clinical or evolve into full systemic illness. A recent expert commission led by Francesco Rubino and colleagues proposes a reframing of obesity into distinct categories of pre-clinical and clinical obesity to reflect differences in organ dysfunction and risk. In the context of metabolic bariatric surgery (MBS), this reframing has important implications for timing of referral, optimisation, and surgical prioritisation.

What is Pre-clinical and Clinical Obesity?

According to the commission, pre-clinical obesity denotes the presence of excess adiposity (i.e., confirmed excess fat mass beyond what BMI alone captures) without measurable impairment of organ or tissue function or significant limitation of daily activities. In contrast, clinical obesity is defined as excess adiposity with demonstrable dysfunction of tissues, organs, or the whole individual, or substantial limitations of day-to-day activities caused by the excess fat. The authors further emphasise that BMI alone is insufficient for individual diagnosis: additional anthropometric or adiposity measurements (e.g., waist-circumference, waist-to-hip ratio, DEXA) and evidence of dysfunction are needed. This conceptual distinction supports more targeted intervention: individuals with pre-clinical obesity have variable level of risk for progression, while those with clinical obesity already require timely therapeutic interventions and may qualify for MBS or metabolic surgery interventions earlier.

Implementation on the NHS: Waiting Lists for Surgery

Within the National Health Service (NHS) context, waiting lists for bariatric and metabolic surgery remain long, and resource constraints challenge prioritisation. The reframing of obesity into pre-clinical and clinical categories offers a framework for triaging surgical referral and optimisation. Patients categorised as clinical obesity (i.e., with established end-organ dysfunction) may warrant expedited surgical pathways, while those with pre-clinical obesity might be managed with intensive medical/pharmacologic optimisation and monitored for progression. Adoption of this stratification could promote more efficient use of surgical capacity, reduce delay for highest-need patients, and potentially reduce downstream burden of complications (e.g., T2DM, renal failure) that drive high costs and morbidity. Real-world data suggest delay in surgery leads to worse outcomes and increased health system burden. Integrating this approach into NHS bariatric services would require protocol development (e.g., pre-surgical assessment for organ dysfunction, metrics of adiposity beyond BMI), updated referral criteria, and collaboration across endocrinology, renal, and surgical services.

Case Discussion

Pre-clinical case: A 34-year-old male with class 3 obesity (BMI 51 kg/m², weight 183 kg) and a history of deep venous thrombosis following a knee dislocation, no metabolic medications or prior abdominal surgery. Although his adiposity is very high, he currently lacks evidence of organ dysfunction and might thus be characterised as pre-clinical obesity under the new framework. Clinical case: A 44-year-old male with class 3 obesity (BMI 57.54 kg/m², weight 160 kg) with osteoarthritis of knee, end-stage renal failure (CKD 5), obstructive sleep apnoea (OSA), type 2 diabetes mellitus (T2DM) with diabetic maculopathy, and multiple antihypertensive and insulin therapies (doxazosin, moxonidine, amlodipine, NovoRapid, Abasaglar). This profile clearly indicates established organ/system dysfunction and fits the definition of clinical obesity. From a surgical-pathway perspective, the pre-clinical patient offers a window for prophylactic care aimed at risk-reduction (which may include metabolic surgery) and perhaps fewer immediate peri-operative risks, whereas the patient with clinical obesity presents both higher surgical risk and higher urgency for metabolic surgery to prevent secondary complications and end-organ damage and improve multiple comorbidities. Classification as “clinical obesity” should prompt expedited evidence-based treatment.

CONCLUSIONS

Within the National Health Service (NHS) context, waiting lists for bariatric and metabolic surgery remain long, and resource constraints challenge prioritisation. The reframing of obesity into pre-clinical and clinical categories offers a framework for triaging surgical referral and medically coherent assessment of urgency of surgical treatment. Patients categorised as clinical obesity (i.e., with established organ dysfunction) may warrant expedited surgical pathways, while those with pre-clinical obesity might be managed on separate surgical waiting lists (akin to polyps and colon cancer). Pre-clinical obesity generally requires prophylactic therapy, which may include lifestyle and monitoring or pharmacologic treatment or even surgery depending on the individual level of health risk/prgression. Adoption of this stratification could promote more efficient use of surgical capacity, reduce delay for highest-need patients, and potentially reduce downstream burden of secondary complications that drive high costs and morbidity.




Figure 1, illustration comparison of pre-clinical and clinical obesity . Pre- clinical case 34 male, security guard workers with a BMI 51kg/m2, weight 183kg with no co-morbidities. Clinical case 44M , unemployed with a BMI 57.5 kg/m2, weight 183 with multiple co-morbidities including severe OSA, insulin dependent T2DM, diabetic retinopathy . Dr Grishma Pradip




Figure 2, Pathway for assessment of excess adiposity, the diagnosis of preclinical and clinical obesity, and the treatment strategies. BMI, body mass index; WC, waist circumference (*102 cm for men, 88 cm for women); WHipR, waist-to-hip ratio (* > 0.90 for men, > 0.85 for women); WHtR, waist-to-height ratio (* > 0.50 for all); DEXA, dual-energy X-ray absorptiometry; MRI, magnetic resonance imaging; MBS, metabolic bariatric surgery; OMM, obesity management medication. Rubino et al 2025.



RESULTS / DISCUSSION

The new classification framework highlights disease severity, rather than simply weight. Earlier access to MBS in pre-clinical obesity may prevent progression to irreversible complications. Patients with clinical obesity often derive the greatest metabolic benefit from surgery, including improved renal function trajectories and diabetes remission. However, they also face higher peri-operative risk and require multi-disciplinary optimisation.

REFERENCES

1. Rubino, F., et al. (2024). A joint international consensus statement classifying obesity into pre-clinical and clinical disease. Obesity Surgery. <https://link.springer.com/article/10.1007/s11695-025-08159-y>

2. Rubino, F., et al. (2020). Metabolic surgery for the treatment of T2DM. The Lancet Diabetes & Endocrinology.

3. Batterham, R., et al. (2023). UK guidance on bariatric/metabolic surgery pathways. NHS England.

4. Rubino, F., Brown, W., Schauer, P. et al. From BMI to Disease Diagnosis: What Clinical and Pre-clinical Obesity Mean for Surgeons. OBES SURG 35, 4559–4564 (2025). <https://doi.org/10.1007/s11695-025-08159-y>

ACKNOWLEDGEMENTS

Many thanks to Professor Francesco Rubino for hiscontinued mentorship.

CONTACT INFORMATION: Grishma.pradip@nhs.net

C. Mendes^{1,2,3}, M. Carvalho^{1,2}, A. Tique^{1,2}, J. Bravo³, S. Martins⁴ and A. Raimundo³

¹ Unidade Local Saúde Alentejo Central - Hospital Espírito Santo de Évora, EPE.

² CRI. COM - Centro Responsabilidade Integrada de Cirurgia da Obesidade e Metabólica.

³ Universidade de Évora, Comprehensive Health Research Centre (CHRC), Évora, Portugal

⁴ Universidade Europeia, Lisboa, Portugal

INTRODUCTION

Strength training and aerobic training have been shown to improve strength and metabolism in patients with obesity. However, the long-term prevalence of sarcopenia after surgery underscores the need for research on both short and long-term exercise programs.

AIM

This study aims to introduce a novel 16-week exercise program based on the FITT-VP (Frequency, Intensity, Time, Type, Volume, Progression) framework, based on American College of Sports Medicine (ACSM) guidelines, designed specifically for bariatric patients to enhance recovery and long-term health outcomes.


METHOD

The proposed exercise protocol, initiated 1-month post-surgery, comprises three progressive phases: resistance (weeks 1-4), hypertrophy (weeks 5-10), and strength (weeks 11-16). The program integrates aerobic and resistance training tailored to the unique needs of bariatric patients. In a controlled randomized trial of post-bariatric surgery, patients (n=36) were assessed for strength, muscle mass, systemic inflammatory index, quality of life, hormonal profile, and body composition pre- and post-intervention.



RESULTS

Preliminary findings indicate significant improvements in muscle strength ($p<0.05$), lean muscle mass ($p<0.05$), and body composition, including reduced fat mass ($p<0.01$). The systemic inflammatory index decreased, reflecting reduced chronic inflammation ($p<0.05$). Participants reported enhanced QoL scores ($p<0.01$) and favorable changes in hormonal profiles, including improved insulin sensitivity and cortisol levels ($p<0.05$). Adherence to the early intervention (1-month post-surgery) was higher compared to delayed initiation attempts at 17 months post-surgery.



CONCLUSIONS

- This 16-week FITT-VP-based exercise program initiated 1-month post-bariatric surgery demonstrates significant benefits in strength, muscle mass, systemic inflammation, quality of life, hormonal profile, and body composition.
- Early exercise intervention appears critical for optimizing patient outcomes and adherence.
- These findings support the integration of structured, phased and combined exercise protocols into post-bariatric care to enhance recovery and long-term health.

REFERENCES




ACKNOWLEDGEMENTS

I would like to express my deepest appreciation to my team. I'm deeply indebted to extend my deepest gratitude to all our patients.

CONTACT INFORMATION

claudia.mendes@uevora.pt



C. Mendes^{1,2,3}, M. Carvalho^{1,2} A. Tique^{1,2} J. Bravo³ S. Martins⁴ and A. Raimundo³

¹ Unidade Local Saúde Alentejo Central - Hospital Espírito Santo de Évora, EPE.

² CRI. COM - Centro Responsabilidade Integrada de Cirurgia da Obesidade e Metabólica.

³ Universidade de Évora, Comprehensive Health Research Centre (CHRC), Évora, Portugal

⁴ Universidade Europeia, Lisboa, Portugal

INTRODUCTION


Obesity is a complex and multifaceted condition that can lead to serious health issues. Bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB), is highly effective treatment for severe obesity but may often leads to significant skeletal muscle loss, compromising long-term metabolic outcomes. Structured exercise may mitigate these effects, yet its impact on comprehensive surgical success remains underexplored.

AIM

This randomized controlled trial evaluated the synergistic effects of a 16-week combined exercise program on the SF-BARI score, a holistic composite measure of weight loss and comorbidity remission, in post-RYGB patients.

METHOD


Thirty-seven patients (mean age 46.9 ± 11.4 years, BMI 42.9 ± 5.14 kg/m²) underwent RYGB and were randomized to a supervised intervention group (IG, n=19) or control group (CG, n=17). The IG completed three 55-minute sessions weekly (aerobic and resistance training) starting one-month post-surgery for 16 weeks. Outcomes, including anthropometry, percentage total weight loss (%TWL), SF-BARI score (integrating %TWL and remission of type 2 diabetes mellitus, hypertension, dyslipidemia, and obstructive sleep apnea), and complications, were assessed at one, five, eleven- and seventeen-months post-surgery.




RESULTS

Both groups achieved substantial weight loss (%TWL: IG 37% vs. CG 32.5% at 17 months, p=0.139, d=0.506), with no between-group differences in BMI or weight. However, the IG showed superior SF-BARI scores at 5 months (104 ± 13.8 vs. 92.3 ± 12, p=0.012, d=0.883) and 11 months (107 ± 13.2 vs. 96.2 ± 16.8, p=0.032, d=0.747), driven by enhanced remission of hypertension (0% vs. 41.2%, p=0.002) and dyslipidemia (0% vs. 23.5%, p=0.025) at 17 months. Type 2 diabetes mellitus remission was high in both (>94%, p=0.935), and effect sizes indicated large clinical benefits in the short-to-medium term.


% Total weight loss




SF- BARI SCORE




SF-BARI SCORE T0



SF-BARI SCORE T6



SF-BARI SCORE T12



CONCLUSIONS

- The SF-BARI score provides a validated, holistic assessment of surgical outcomes by combining %TWL with remission status of key comorbidities, offering superior sensitivity over isolated metrics.
- A 16-week supervised combined aerobic-resistance exercise program yielded comparable %TWL to controls but significantly higher SF-BARI scores in the short-to-medium term, primarily through superior hypertension and dyslipidemia remission.
- Exercise amplified surgery-induced gains, with no increase in complications.

REFERENCES



ACKNOWLEDGEMENTS

I would like to express my deepest appreciation to my team. I'm deeply indebted to extend my deepest gratitude to all our patients.

CONTACT INFORMATION

claudia.mendes@uevora.pt

KK. Bjerk¹, ÅA. Hyldmo², S. Nymo^{2,3}, DAL. Hoff^{1,2}, J. Sandvik^{1,2}.

1 Ålesund Hospital, Møre and Romsdal Hospital Trust, Ålesund, Norway.

2 Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.

3 Namsos Hospital, Nord-Trøndelag Hospital Trust, Namsos, Norway.

INTRODUCTION

There are limited knowledge of dental problems in patients after bariatric surgery.

AIM

To examine saliva secretion and self-reported dental health in patients long-term after RYGB.

METHOD

12 Years after RYGB

171 Patients measuring saliva flow.

 Resting saliva for 15 min.
Hyposalivation: < 0.1 mL/min

 Stimulated saliva with chewing wax for 5 min.
Hyposalivation: < 1.0mL/min

pH and buffering ability

 Dental health was assessed by self-reported questionnaire.

RESULTS

 **131 / 40**
53 Years 

Pre op BMI 43 kg/m²

Present BMI 33 kg/m²

Saliva secretion test results:	Test at rest	Stimulated test
Patients with hyposalivation	106 (62%)	60 (35%)
Saliva ml/min, mean ± SD	0.35 ± 1.1	1.6 ± 1.9
pH, mean ± SD	6.6 ± 0.4	7.4 ± 0.3
Patients with resting pH < 6.8	136 (80%)	
Patients with stimulated pH < 7.3		61 (36%)
Buffering ability, mean ± SD		7.5 ± 3.0
Patients with buffering ability < 9		118 (69%)

CONCLUSIONS

More than half of the patients have hyposalivation at rest and one third in stimulated state. There are more patients suffering from hyposalivation than self-reported dry mouth.

Patients with low stimulated saliva are 2.2 times more likely to report poor dental health compared to their counterparts with normal saliva flow.

REFERENCES


1. Jonsson M. et. al. Diagnosing oral dryness and use of saliva as a diagnostic fluid. Nor Tannlegeforen Tid 2011;121(14):908–13.
2. Marsicano JA. et al. Evaluation of oral health status and salivary flow rate in obese patients after bariatric surgery. Eur J Dent. 2012;6(2):191–7.
3. de Moura-Grec PG. et. al. Impact of bariatric surgery on oral health conditions: 6-months cohort study. Int Dent J. 2014;64(3):144–9.

ACKNOWLEDGEMENTS

Thanks to the participants, the staff at Clinical Research Unit, Møre and Romsdal Hospital Trust, Ålesund for their invaluable effort in data collection.

CONTACT INFORMATION

Kirsti.Kverndokk.Bjerk¹@helse-mr.no



C. Mendes^{1,2,3}, M. Carvalho^{1,2}, A. Tigue^{1,2}, J. Bravo³, S. Martins⁴ and A. Raimundo³

¹ Unidade Local Saúde Alentejo Central - Hospital Espírito Santo de Évora, EPE.

² CRI. COM - Centro Responsabilidade Integrada de Cirurgia da Obesidade e Metabólica.

³ Universidade de Évora, Comprehensive Health Research Centre (CHRC), Évora, Portugal

⁴ Universidade Europeia, Lisboa, Portugal

INTRODUCTION


Bariatric surgery is an effective intervention for severe obesity, but long-term optimal success relies on sustained self-care behaviors, self-efficacy for exercise, and weight management. Nurse-led case management has shown promise in enhancing patient outcomes, yet robust evidence from randomized controlled trials (RCT) remains limited.

AIM

This study evaluated the impact of a nurse-led case management intervention (NURLIFE) on pre- and post-operative weight loss and self-care behaviors in bariatric patients.



METHOD

A single-center RCT was conducted from January 2024 to August 2025 in a public hospital in southern Portugal. Forty patients were randomized to an intervention group (IG, n=20) receiving NURLIFE (personalized counseling, goal setting, and follow-up) or a control group (CG, n=20) receiving standard care. Outcomes, including weight, Self-Care of Chronic Illness Inventory (SCII), Self-Efficacy for Exercise (SEE), and Social Appearance Anxiety Scale (SAAS), were assessed at baseline, pre-surgery, and 12 months post-surgery.



RESULTS

The IG exhibited significant pre-operative weight loss (7.36 ± 7.09 kg vs. -0.10 ± 7.33 kg in CG, $p = 0.001$, $d = -1.03$), which was maintained and extended post-surgery (50.83 ± 13.55 kg vs. 42.35 ± 19.81 kg, $p = 0.061$). Significant improvements were observed in SCII Maintenance ($p = 0.012$, $d = -0.74$) and SEE ($p = 0.004$, $d = -0.90$) at 12 months, with no significant differences in SAAS or other SCII domains. The absence of significant post-operative weight loss differences suggests that pre-operative gains were sustained.



Case Management flowchart

Variables		Before Surgery		After Surgery			Group		Moment*Group	
		Baseline	Pre-Op	2-month	6-month	12-month	p	η²	p	η²
Mean ± SD		T0	T1	T2	T3	T4				
Weight (kg)	Control group	117±13.3	117±8.86	98.6±8.66	76.9±8.66	75±10.8	0.061	0.089	0.230	0.038
	Intervention group	119±9.82	112±6.45	94.8±11.9	73.3±8.58	68.1±8.14				
BMI (kg/m²)	Control group	44.5±5.46	44.6±4.30	37.4±3.65	29.2±3.65	28.5±4.34	0.050	0.093	0.274	0.033
	Intervention group	44.4±3.30	41.8±3.56	35.5±5.15	27.5±4.00	25.5±3.48				
SCII Maintenance	Control group	51.8±6.11	53.8±4.65	54.6±4.85	57.1±3.54	57.8±2.54	0.231	0.038	<0.001	0.124
	Intervention group	49.4±5.57	51.3±4.16	57.9±2.63	60.0±0.08	60.0±0.01				
SCII Monitoring	Control group	49.9±5.20	53.4±5.59	55.5±4.87	56.5±3.98	57.6±2.80	0.002	0.226	0.408	0.026
	Intervention group	50.3±5.71	56.5±4.11	58.3±2.42	59.8±0.56	60.0±0.01				
SCII Management	Control group	48.8±6.09	52.1±5.27	56.2±4.92	57.9±3.38	58.2±2.28	0.001	0.248	0.321	0.030
	Intervention group	49.1±5.50	56.2±4.42	58.2±2.60	59.8±0.44	60.0±0.01				
SCII Confidence	Control group	49.4±5.12	54±5.53	55.5±4.37	55.5±4.20	57.2±3.13	<0.001	0.319	0.316	0.030
	Intervention group	52.4±5.72	54.6±5.63	58.9±2.06	59.8±0.47	60.0±0.01				
SEE	Control group	43.4±7.35	42.7±5.07	46.7±6.77	46.8±6.75	47.3±5.74	<0.001	0.511	0.030	0.068
	Intervention group	43.4±6.61	48.9±5.58	50.9±5.02	53.5±2.61	54.5±1.09				
SAAS	Control group	55.3±5.66	52.0±4.90	50.4±5.21	52.2±4.95	48.2±4.26	<0.001	0.396	0.018	0.075
	Intervention group	53.7±5.61	51.7±5.12	47.1±3.17	45.3±0.71	45.0±0.01				

CONCLUSIONS

- Specialized perioperative nurse case managers, through personalized support and follow-up, significantly increase pre-operative weight loss, which is maintained and extended after surgery.
- This research compares intervention group receiving tailored nurse-led support to a control group receiving standard care, offering insights into the role of perioperative nursing in optimizing patient-centered care.
- The results support the integration of structured nurse-led interventions into perioperative care, aligning with global priorities for improving chronic disease management and bariatric surgery outcomes.

REFERENCES



ACKNOWLEDGEMENTS

I would like to express my deepest appreciation to my team. I'm deeply indebted to extend my deepest gratitude to all our patients.

CONTACT INFORMATION

claudia.mendes@uevora.pt

INTRODUCTION

Laparoscopic sleeve gastrectomy is a recognised surgical treatment for patients living with obesity. Currently, the National Health Service offers this treatment to individuals with a Body Mass Index above 40, or over 35 if diagnosed with obesity-related health conditions such as diabetes, hypertension, osteoarthritis and sleep apnoea.

AIM

To evaluate the long-term impact of Laparoscopic Sleeve Gastrectomy as a treatment for patients living with diabetes, hypertension, osteoarthritis and sleep apnoea.

Furthermore, to assess the effect of Laparoscopic Sleeve Gastrectomy on gastric reflux symptoms.

METHOD

This was a retrospective study using data collected from patients who underwent Laparoscopic Sleeve Gastrectomy at St George’s Hospital, London between January 2016 and December 2017.

Patients were followed up by telephone at 40-months and asked to take part in a questionnaire to assess changes in the management of their obesity-related medical conditions.

Outcomes were based on adjustments to the number or dose of medical therapies being used for obesity-related conditions compared to before surgery.

Patients were categorised into groups showing either resolution, improvement, deterioration or no change in their obesity-related diabetes, hypertension, osteoarthritis and sleep apnoea. Patients were also questioned about symptoms of gastric reflux.

RESULTS

A total of 76 patients patients were included in the study, having undergone laparoscopic sleeve gastrectomy at our hospital between 2016 and 2017 and providing follow up data.

The effect of surgery on obesity-related medical conditions is summarised below:

Hypertension (34/76 patients):

- 6/34 resolved, 15/34 no change, 13/34 deteriorated

Diabetes Mellitus (29/76 patients):

- 12/29 resolved, 12/29 no change, 5/29 deteriorated

Osteoarthritis (24/76 patients):

- 24/24 reported no change in symptoms

Sleep Apnoea (18/76 patients):

- 3/18 resolved, 1/18 improved, 13/18 no change, 1/18 deteriorated

Gastric Reflux (20/76 patients):

- 2/20 resolved, 3/20 improved, 3/20 no change, 12/20 deteriorated

CONCLUSIONS

Overall, laparoscopic sleeve gastrectomy has been shown to offer a good level of resolution/ improvement in obese patients with diabetes mellitus. There were mixed outcomes in the hypertension group and only modest improvement for those suffering with sleep apnoea. Data showed very little improvement in patients with osteoarthritis.

On the other hand, gastric reflux is commonly aggravated, which is a commonly recognised post-operative side-effect after laparoscopic sleeve gastrectomy.

Co-morbidity (number of patients)	% Resolved	% Improved	% No change	% Deteriorated
Hypertension (34)	17.6%	-	44.1%	38.2%
Diabetes mellitus (29)	41.4%	-	41.4%	17.2
Osteoarthritis (24)	0	-	100%	-
Sleep apnoea (18)	16.7%	5.6%	72.2%	5.66%
Gastric reflux (20)	10%	15%	15%	60%

TABLE 1: Percentage of patients who showed resolution, improvement, no change or deterioration in obesity-related medical co-morbidities 40-months after undergoing Laparoscopic Sleeve Gastrectomy

REFERENCES

Himpens J, Dobbela J, Peeters G. Long-term results of laparoscopic sleeve gastrectomy for obesity. Ann Surg. 2010 Aug;252(2):319-24.

National Institute for Health and Care Excellence (2025). *Overweight and obesity management*. NICE guideline [NG246].

Davrieux CF, Palermo M, Nedelcu M, Nocca D. Reflux After Sleeve Gastrectomy: An Update. J Laparoendosc Adv Surg Tech A. 2021 Sep;31(9):978-982.

ACKNOWLEDGEMENTS

We would like to express our thanks to all the patients who agreed to take part in this study.

CONTACT INFORMATION

Husayn Esmail: Husayn.Esmail@nhs.net

A56- Impact of surgical training on long-term patient outcomes undergoing Laparoscopic Sleeve Gastrectomy

A. GHOSH¹, H. ESMAIL², O. KHAN³

St George's University Hospitals NHS Trust, London, United Kingdom

INTRODUCTION

Laparoscopic sleeve gastrectomy is a commonly practised bariatric procedure to achieve weight loss in the obese population. Surgical outcomes can often be linked to operator experience and training.

AIM

To compare weight loss outcomes between Consultants and Clinical Fellows/ Surgical Trainees undertaking Laparoscopic Sleeve Gastrectomy as the lead operator.

METHOD

We conducted a retrospective analysis on patients undergoing Laparoscopic Sleeve Gastrectomy between January 2016 and December 2017, with either a Consultant or Trainee as the lead operator.

Patient demographics, such as obesity-related co-morbidities, age, gender and pre-operative BMI were comparable, in order to minimise bias between the two groups.

We compared operating time, length of stay, complications and excess body weight loss to determine if there was a difference in outcomes based on the experience/ grade of the lead operator.

At 20 months and 40 months post-operatively, a telephone audit was conducted to calculate excess weight loss for each patient, as well as document any complications to compare long-term outcomes between the two groups.

RESULTS

- **76 LSG patients were included:**

- 44 performed by Consultants
- 32 performed by Trainees

- No difference in age, gender, pre-operative weight/ BMI and number of obesity-related comorbidities between groups.

- **Operative time:**

- Consultants 91 ± 18.1 minutes
- Trainees 105 ± 10.0 minutes

- **Length of stay:**

- Consultants 2.8 ± 0.9 days
- Trainees 2.6 ± 0.4 days

- **Complications:**

- Consultants 2 (wound infection, intra-operative bleeding with ICU admission)
- Trainees 3 (intra-abdominal collection requiring drainage, wound infection and hypokalaemia)

- **Excess Weight Loss (%) at 20 months ($p=0.49$):**

- Consultants 52.4 ± 6.7
- Trainees 55.9 ± 7.5


- **Excess Weight Loss (%) at 40 months ($p=0.54$):**

- Consultants 50.7 ± 9.9
- Trainees 54.9 ± 9.9

CONCLUSIONS

Overall, our results demonstrate that short and longer-term outcomes of Laparoscopic Sleeve Gastrectomy are similar between both groups, regardless of whether the lead operator is the Consultant or the Trainee.

The data suggests weight loss outcomes are comparable, and supports the notion that adequately-supervised trainee-led procedures are a viable method of surgical training.



REFERENCES

- Mocian F, Coroş M. Laparoscopic sleeve gastrectomy as a primary bariatric procedure: postoperative outcomes. Med Pharm Rep. 2021 Apr;94(2):208-213.
- Masry MAME, Fiky MAME. Long-Term Outcome of Laparoscopic Sleeve Gastrectomy (LSG) on Weight Loss in Patients with Obesity: a 5-Year and 11-Year Follow-Up Study. Obes Surg. 2023 Oct;33(10):3147-3154.
- Goldberg I, Yang J, Park J, Pryor AD, Docimo S Jr, Bates AT, Talamini MA, Spaniolas K. Surgical trainee impact on bariatric surgery safety. Surg Endosc. 2019 Sep;33(9):3014-3025.

ACKNOWLEDGEMENTS

We would like to express our thanks to all the patients who agreed to take part in this study.

CONTACT INFORMATION

Husayn Esmail: Husayn.Esmail@nhs.net